Uncategorized
BUFFALO, N.Y., March 27, 2018 — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Simon Pedder, Chief Business and Strategy Officer, will present at the 17th Annual Needham Healthcare Conference in New York City on Tuesday, March 27, 2018 at 2:00 pm EDT.
The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available on this website until April 27, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
March 27, 2018
- Pivot Pharmaceuticals attains prestigious CSE25 status
- Recent acquisitions have extended the company’s portfolio in the cannabis space
- Numerous pharmaceutical and nutraceutical products in development pipeline
Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) announced on March 19, 2018, that it has been named to the CSE25 Index (http://cnw.fm/g1qK7). CSE25 is a conglomerate of the 25 largest companies by market capitalization listed on the Canadian Securities Exchange. This achievement adds to Pivot Pharmaceuticals’ status as a constituent of the CSE Composite Index, which provides a distinctly different risk/return profile than the broad Canadian equity market.
“With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated in the news release. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.”
In February 2018, Pivot Pharmaceuticals entered into a letter of intent for the acquisition of Agro-Biotech Inc., a cannabis cultivator located in Quebec. Agro-Biotech received its producer’s license on January 12, 2018. On completion of the proposed acquisition, Pivot will be able to conduct research and development and store cannabis derivatives not currently covered under ACMPR regulations. The company will also be in a position to process natural health products and export cannabis oils and concentrates to international markets, once it receives an export permit.
The company’s recent acquisitions also include Thrudermic, LLC, a company based in North Carolina that has developed a transdermal, lipid-based nano-dispersion technology for cannabinoid delivery. Pivot also acquired ERS Holdings, LLC in February 2018, a California-based company that holds patents for the production of powderized cannabis oil that can be added to beverages and baked goods.
Pivot Pharmaceuticals is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals through proprietary drug delivery technologies via medical cannabis product division Pivot Green Stream Health Solutions (“PGS”). In early February 2018, the company announced that it had filed three provisional patents for cannabinoid-based product delivery technologies with the U.S. Patent Office. These are for its innovative transdermal nanotechnology, inhalation and mucus topical delivery platforms. Its BiPhasix™ Transdermal Drug Delivery technology has been tested in clinical trials approved by both the FDA and EMA. This delivery platform provides significant advantages over oral delivery technologies.
Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://cnw.fm/32ENj). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.
For more information, visit the company’s website at www.PivotPharma.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
March 27, 2018
- Leadership team leveraging years of experience to sustainably meet company’s goals
- Organic growth, single payment processing platform that integrates any payment ecosystem among top goals for 2018 and beyond
- Payment processing industry set to reach $2.2 trillion by 2021
On the heels of a remarkable performance in 2017, which ended with the strongest balance sheet in the company’s history and a $7.55 million investment, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) is targeting sustained organic growth across all sectors, as well as significant advancements in blockchain developments. With a highly experienced and committed management team at the helm, bringing a unique blend of vision, leadership and creative energy, the company looks all but set to achieve its goals for 2018 and beyond.
The overall vision, strategy and execution of Net Element’s mission are in the hands of its CEO and director, Oleg Firer. Recognized as one of the top entrepreneurs in Florida and one of the most influential people in Miami by publications such as Business Leader Magazine, Forbes and Poder Magazine, Firer served as executive chairman of Unified Payments before taking his current position. During his tenure, Unified Payments was ranked as the fastest-growing company in 2012 by Inc. Magazine, having grown its revenues by 23,646 percent over a three-year period. Unified Payments, which provides various payment processing services, including mobile payment acceptance to small- and medium-sized merchants, was acquired by Net Element in April 2013. Firer is leveraging his experience and skills to help drive Net Element’s sustained growth and achieve the group’s long-term goal of creating a single, international processing platform.
The company’s chief technology officer, Andrey Krotov, is an experienced software engineer originating from Russia. He first joined Net Element as a senior software developer in early 2011 but soon became head of Net Element Russia’s development department, where he remained until March 2014, when he took his current management position. He previously worked as a software engineer and senior software engineer with software development companies such as Interactive Tribe GmbH and Artsofte. With a master’s degree from Russia’s Ural State Technical University, Krotov has focused throughout his career on the creation of proprietary intellectual property and the management of both local and outsourced software developing teams. He will use his expertise to continue overseeing and coordinating Net Element’s product development efforts.
With a BS in accounting from Florida State University and vast experience in providing financial and accounting services to a number of companies, Jonathan New has served as chief financial officer of Net Element since 2008. Before joining Net Element, he provided auditing, reporting and corporate accounting services to different public companies. He is a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants.
Net Element’s chief legal officer and secretary, Steven Wolberg, is an experienced attorney who has been practicing for years in both the United States and South Africa. Wolberg is a member of the Massachusetts Bar Association; he received his bachelor of laws from the University of Witwatersrand in Johannesburg and his juris doctorate from the New England School of Law in Boston. He has served as chief legal officer of Net Element since 2013, before which he served in various capacities with Acies Corporation, a financial services and payment processing company, and several other firms.
As the global payments industry continues to thrive and is expected to surpass $2.2 trillion dollars in volume by 2021 (http://nnw.fm/49lVU), Net Element is set to strengthen its position as a leading developer and provider of innovative payment solutions. Supporting electronic payments acceptance in a multi-channel environment, from mobile devices to blockchain, e-commerce and point-of-sale, the company remains focused on continuing its organic growth, developing innovative payment solutions, especially in the field of blockchain and, ultimately, creating a single onboarding and transaction processing platform that will accommodate both local and international payment ecosystems.
For more information, visit the company’s website at www.NetElement.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels
Clinically relevant secondary endpoints were also met, including statistically significant, progressive improvements in COPD symptoms
RPL554 was well tolerated at all dose levels in this four week 400 patient study
Management to hold conference call and webcast today at 8 am EDT / 1 pm BST
LONDON, March 26, 2018 — Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today positive top-line data from its Phase 2b study evaluating RPL554, a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 with bronchodilator and anti-inflammatory properties, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
The study met its primary endpoint, with RPL554 producing a clinically and statistically significant improvement in peak forced expiratory volume in one second (FEV1) at four weeks in patients with moderate-to-severe COPD compared to placebo. Furthermore, the peak FEV1 was significantly improved at all time points over the four weeks of dosing. Secondary endpoints measuring 12 hour average FEV1, COPD symptoms and Quality of Life were also met and support the potential clinical benefits of RPL554 for the treatment of COPD.
The four-week, double-blind, placebo-controlled, parallel group, Phase 2b multicenter European study performed in the out-patient setting evaluated the efficacy, safety, and dose-response of nebulized RPL554 administered twice-daily as a maintenance treatment for COPD in 403 patients with moderate-to-severe COPD. There were four dosing arms of RPL554 (0.75 mg, 1.5 mg, 3.0 mg and 6.0 mg) in the study in addition to placebo and patients were required to withhold use of regular long-acting bronchodilator therapy for the duration of the study.
Highlights
Primary endpoint:
- RPL554 met the primary endpoint at all doses, showing a statistically significant difference vs. placebo (p<0.001) with absolute changes from baseline >200mL in peak FEV1 after 4 weeks of dosing. No minimum effective dose could be determined.
- This peak bronchodilator effect was observed at the first dose and was sustained over four weeks (p<0.001).
Secondary endpoints include:
- Statistically significant improvements in average FEV1 over 12 hours were observed at all doses after the first administration, and this effect was sustained over four weeks.
- This study did not demonstrate consistent improvements in trough FEV1.
- Recording of daily COPD symptoms, using E-RS (EXACT-PRO)1, demonstrated a significant improvement in total COPD symptoms (p<0.002), including improvements in breathlessness (p<0.02), chest symptoms (p<0.02), and cough and sputum (p<0.02).
- Strong trend of improvement in SGRQ-C2 of >2.5 units was observed in all dose groups after four weeks.
- Patients’ Global Impression of Change3 indicates that patients felt better on RPL554 compared to placebo (p<0.01).
- RPL554 was well tolerated at all doses with an adverse event profile similar to placebo.
Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester, a Lead Investigator in the study, commented, “The results from this relatively large and well-designed study are very encouraging and clinically meaningful. The large and sustained improvement in lung function and reduction in COPD symptoms, including reduction in breathlessness, are particularly noteworthy. When coupled with the drug’s unique mechanism of action, these data underline the potential for RPL554 as a new complementary treatment for patients with this progressive and debilitating disease, where there remains a high unmet medical need.’’
Verona Pharma’s CMO, Ken Newman, M.D. said, “I am delighted that we met the primary endpoint of peak FEV1, confirming the strong bronchodilator effect of RPL554 in COPD patients. The clinically meaningful improvement in daily reported COPD symptom scores in all sub-domains, that continued to improve over the four week treatment period, is particularly exciting and promising.’’
“These results are very encouraging and strongly support the progression of RPL554 into later stage development as an inhaled treatment for COPD patients”, said Jan-Anders Karlsson, PhD., CEO of Verona Pharma. “The future clinical development and the positioning of this novel treatment will be informed by these data as well as by the outcome of the clinical study as an add-on to established combination therapies planned to start this year, and our ongoing market research”.
In previous clinical trials, RPL554 has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva®), compared with such bronchodilators administered as a single agent. In addition, RPL554 has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. In these studies, RPL554 has been well tolerated. RPL554 also has a favorable safety and tolerability profile, having been administered in more than 730 subjects in 12 clinical trials.
1 E-RS (EXACT-PRO) – a recognized patient-reported outcome measure for use in clinical studies of COPD.
2 SGRQ-C – St. George’s Respiratory Questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD.
3 Patients’ Global Impression of Change – a scale reflecting the patient’s belief about the efficacy of treatment.
Conference Call
Verona Pharma will host an investment community conference call today at 8:00 a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) to discuss the positive top-line data from the Phase 2b clinical trial in COPD disclosed in this press release.
Analysts and investors may participate in the conference call by utilizing the conference ID: 13677941 and dialing the following numbers:
- 1-877-423-9813 or + 1-201-689-8573 for callers in the United States
- 0 800 756 3429 for callers in the United Kingdom
- 0 800 182 0040 for callers in Germany
Those interested in listening to the conference call live via the internet may do so by visiting the “Events and Presentations” page on the “Investors” section of Verona Pharma’s website at http://investors.veronapharma.com/events-and-presentations/events and clicking on the webcast link. Slides highlighting the top-line data will also be posted to the “Events and Presentations” page.
About COPD
Chronic obstructive pulmonary disease (COPD) is a progressive and life-threatening respiratory disease for which there is no cure.1 The condition damages the airways and the lungs, leading to persistent breathlessness, impacting a person’s daily life and their ability to perform simple activities such as walking a short flight of stairs or carrying a suitcase.1 Although COPD is thought to be underdiagnosed, globally, around 384 million people suffer from the disease.2 This number, according to the World Health Organization (WHO), is likely to increase in coming years, with estimates that COPD will become the third leading cause of death worldwide by 2030.1,[3] Current COPD therapies focus on reducing and controlling symptoms. Yet, despite the wide availability of these treatments, many patients continue to suffer acute periods of worsening symptoms known as exacerbations. These exacerbations often lead to emergency department visits or hospital admissions and are also associated with high mortality.4 In the United States alone, the 2010 total annual medical costs related to COPD were estimated to be $32 billion and are projected to rise to $49 billion in 2020.5
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.
Forward-Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the value of the top-line results from the Phase 2b clinical trial, RPL554 as a new complementary treatment for patients with COPD, projected annual medical costs related to COPD, the results of the Phase 2b trial supporting later stage development of RPL554, the future clinical development and positioning of RPL554, and the treatment potential for RPL554.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of RPL554, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of RPL554, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with RPL554, which could adversely affect our ability to develop or commercialize RPL554; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing RPL554 for multiple indications; our ability to obtain approval for and commercialize RPL554 in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize RPL554; and lawsuits related to patents covering RPL554 and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018 relating to our Registration Statement on Form F-1, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.
For further information, please contact:
| Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer |
info@veronapharma.com |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison |
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com |
|
|
| FTI Consulting (UK Media and Investor enquiries) |
Tel: +44 (0)20 3727 1000 |
| Simon Conway / Natalie Garland-Collins |
veronapharma@fticonsulting.com |
|
|
| ICR, Inc. (US Media and Investor enquiries) |
|
| James Heins |
Tel: +1 203-682-8251
James.Heins@icrinc.com |
| Stephanie Carrington |
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com |
1 World Health Organization. Chronic Obstructive Pulmonary Disease. http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed September 2017.
2 Adeloye D, Chua S, et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J Glob Health 2015; 5(2): 020415.
3 World Health Organization. Burden of COPD. http://www.who.int/respiratory/copd/burden/en/. Accessed September 2017.
4 COPD Foundations. Characteristics of COPD Patients Using United States Emergency Care or Hospitalization. https://journal.copdfoundation.org/jcopdf/id/1103/Characteristics-of-COPD-Patients-Using-United-States-Emergency-Care-or-Hospitalization. Accessed September 2017.
5 Center for Disease Control. Increase Expected in Medical Costs for COPD. https://www.cdc.gov/features/ds-copd-costs/. Accessed September 2017.
March 26, 2018
- ETST revenue increased by 90 percent in the month of February
- Research demonstrates that ETST’s CBD oil offers top nutritional and supplement value
- Newly appointed chief sales officer and chief learning officer opening innovative avenues
Earth Science Tech, Inc. (OTC: ETST) announced on March 13, 2018, that February marked the company’s highest-ever sales revenue month. The innovative biotech company focuses on cannabidiol (CBD) nutraceutical and pharmaceutical fields, along with its provision of R&D for certain medical devices. In February, the company achieved a 90 percent revenue increase, from $39,881 to $75,981. The company attributed this increase to its new veteran chief sales officer, supported by a CBD line that has undergone a revamp (http://nnw.fm/Q5tzv).
Earth Science Tech possesses among the highest quality and purity full-spectrum hemp CBD oil on the market. The product is made through critical CO2 extraction processes, making ETST’s CBD oil 100 percent organic and natural. Working alongside DV Biologics and the University of Central Oklahoma, ETST’s research demonstrated that the company is the top nutritional and supplement brand for high-grade hemp CBD oil (http://nnw.fm/AI2dp).
In a news release, Nickolas Tabraue, company president, director and COO, noted February to be a pivotal month, giving praise to newly appointed CSO Jill Buzan while appointing Gabriel Aviles as the company’s chief learning officer. “Jill Buzan has brought so much to our company, and with her experience and knowledge Earth Science Tech, Inc. truly looks to stay innovative and be the trusted CBD brand in the industry,” Tabraue stated, further mentioning that Aviles has begun recording live videos from Monday through Friday on the company’s YouTube channel. Through this endeavor, individuals will have the opportunity to learn more about CBD and will be able to ask questions in real-time, with the videos being shared on social media.
Commenting on the achievement, CSO Jill Buzan stated, “My first month with the company has been an amazing experience with so much potential. I’m excited to see that we were able to achieve the highest revenue month to date, especially due to product delivery delays and slight errors made from the manufacture.”
Tabraue confirmed that the new product revamp has been successful, despite minor errors and manufacturing delays resulting from the increased product demand that was experienced. “We are currently working on our next batch, improving our formula and providing adequate manufacturing time to eliminate any potential errors and to prevent backorders,” Tabraue continued.
Tabraue goes further to say that ETST’s audit continues to move forward and is set to be finalized before the end of March. The audit will be used to submit the company’s planned Tier II Regulation A+ offering, alongside its planned OTCQB up listing. “The team and I greatly appreciate our stakeholders’ loyalty, trust and support while growing with us. We plan on sharing updates as they progress,” reaffirmed Tabraue. With February proving to be a fiscal milestone for Earth Science Tech, Inc., it can be expected that the newly introduced leadership will bring further innovative changes within this fast-growing industry.
For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
VANCOUVER, March 26, 2018 – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”), is pleased to announce that the Company has successfully completed the integration of its California subsidiary, ERS Holdings Ltd., under the guidance of Mr. Patrick Rolfes, President of Pivot Pharmaceuticals USA. Mr. Rolfes continues to surround himself with proven, well-respected and experienced leaders in the scientific, legal, financial, and marketing and branding fields. As Pivot prepares for product launch in California in 2018, a consumer-facing brand is being developed for the entire company and will be unveiled in the coming weeks. New websites and marketing materials for our various subsidiaries are also under development. A product list based on our industry-leading and patented bio-cannabis formulation and delivery technologies will be available for consumers and retailers in the coming months.
The Company also wishes to announce that it has secured a listing on the Frankfurt Stock Exchange (“FSE”) and has commenced trading under the symbol “NPAT”. The FSE is one of the world’s largest trading centres for securities, and the largest of Germany’s seven stock exchanges. The Company believes the listing in Germany will give it greater exposure to a European-based investor audience, fuelling interest and liquidity in Pivot. The Company’s shares continue to trade on the OTCQB and the Canadian Securities Exchange.
Mr. Rolfes comments that “We are a health and wellness manufacturing company whose branded products incorporate patented scientific processes to bring cannabinoid-based derivatives to the market in discreet and consistent dosages with significant, targeted health benefits and superior bioavailability.” Mr. Rolfes added that “Pivot’s consumer-facing brands, backed by our patented technologies and formulations, will provide health conscious consumers with natural edible and topical cannabis products delivering exceptional targeted results which will quickly differentiate Pivot in the cannabis space.”
A report from the cannabis industry research firm BDS Analytics estimates sales of cannabis in California to hit USD $3.7 billion by the end of 2018 alone, and predicts that number will increase to USD $5.1 billion in 2019 as more dispensaries come online. For comparison, beer sales in the state hit USD $5 billion in 2017, according to industry research group IBIS World. California, the world’s sixth largest economy with a population of close to 40 million, will form a massive portion of the total market for cannabis in North America.
Dr. Patrick Frankham, Pivot’s CEO, states “As the Company prepares for legalization of cannabis in Canada, we continue to expand our business operations in the US market on a state-by-state basis, where regulations permit. California alone has a population four million people higher than Canada and the potential cannabis market size speaks for itself. During recent strategy sessions with Pivot USA, we finalized plans for Mr. Rolfes and his experienced team to launch Pivot’s consumer-facing brands through Pivot’s wholly-owned California licensed manufacturing facility, coming online later this year. Creating value for shareholders is of the utmost importance and I am confident that their investment will be rewarded in the weeks and months ahead.”
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology. BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com
Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc. or Pivot Pharmaceuticals USA Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
SAN GABRIEL, California, March 26, 2018 —
ChineseInvestors.com Inc. (OTCQB:CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, announces that it will sponsor at the 2018 National Investment Bankers Association (“NIBA”) meeting taking place on March 27, 2018, in New York City at the Westin Hotel in Times Square.
ChineseInvestors.com, Inc.’s CEO Warren Wang will provide a video interview that will be available for viewing on NIBA’s website highlighting the Company’s business updates including: (1) its newly launched cryptocurrency focused website http://www.newcoins168.com, a Bitcoin and blockchain information and education platform that provides the most up-to-date cryptocurrency news and crypto investment education for the global Chinese community; (2) its recent partnership with Phoenix North America Chinese Channel, one of the most influential and globally renowned Chinese television broadcasters, with plans to broadcast a daily cryptocurrency commentary program, “Bitcoin Big Winner,” and its “Wall Street Daily Program ” with up-to-date roadshow and conference reports; and (3) the Company’s investor relations service plans designed to achieve specific marketing objectives through roadshows, newsletters and TV Broadcasts.
Since 1982, the National Investment Banking Association has been a not-for-profit association comprised of micro-cap and small-cap professionals including Broker Dealers, Investment Bankers, RIA’s, Private Equity Groups, Family Offices, Boutique Corp. Finance, Specialized Investment Brokerages, Venture Capital Groups, Fund Managers, and Capital Market Service Providers, etc. NIBA has hosted 143 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry. NIBA’s member firms have a 37-year track record of successfully completing thousands of transactions totaling over $15 billion in new capital for emerging growth companies and are responsible for 90% of all IPOs under $20 million.
“CIIX is pleased to sponsor at NIBA’s upcoming New York City meeting and looks forward to the opportunity to network with top micro-cap and small-cap professionals,” says CIIX Founder and CEO Warren Wang. “We look forward to greeting attendees at our booth where they can learn more about CIIX and the incredible opportunities ahead.”
About ChineseInvestors.com (OTCQB: CIIX)
Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.
For more information, visit ChineseInvestors.com
Visit and register: https://www.newcoins168.com
Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom
Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured
Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh
Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom
https://www.facebook.com/Chineseinvestors.com.english
Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776
Investor Relations:
Alan Klitenic
+1-214-636-2548
Corporate Communications:
NetworkNewsWire (NNW)
New York,
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com
VANCOUVER, British Columbia, March 26, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to provide an update of the extensive process testing work and pilot plant design being performed by the Company’s Scientific Advisory Team. The Scientific Advisory Team and other technology vendors have been testing raw lithium brines from Standard Lithium’s Projects in California and Arkansas using a new generation of lithium-selective sorbent technologies. Data gathered from mini-pilot scale testing has demonstrated highly-effective separation of lithium from other cations in the raw brine, in line with previously published and peer-reviewed studies, and has also demonstrated that the solid sorbent materials can be simply made using standard commercial manufacturing processes. Work has also been completed to test varying physical methods by which raw brine can be mixed with the lithium-selective material to optimise lithium removal. Testing is ongoing and will be used in the full-scale pilot design (see below).
Standard Lithium is also pleased to announce that they have engaged Zeton Inc. to design and build the full-scale continuous pilot plant for deployment in southern Arkansas. Zeton Inc. is based in Burlington, Ontario, and is the largest designer and builder of modular pilot/demo scale plants in the world, having completed over 800 projects in over 35 countries. Design basis engineering has commenced, and it is expected that construction of the various modules will commence in the second half of 2018.
President and Chief Operating Officer, Dr. Andy Robinson, commented, “Standard’s Scientific Advisory Team has been extremely busy over the last six months developing and adapting existing brine processing technologies to integrate modern lithium-selective technologies; both constructing new mini-pilot scale facilities, as well as working with other third-party technology vendors. We’re now in a position where we have demonstrated proof-of-concept for these technologies and can optimise process flowsheets for the Arkansas and California lithium brines. We’re also delighted to be working with the team at Zeton Inc. and benefitting from their huge depth of experience when it comes to designing and building continuously operated, fully integrated modular Pilot Plants. In order to effectively manage the Pilot Plant design and build process, we’ve also added significant senior engineering bench strength to Standard’s team, and we look forward to providing more information on the Pilot Plant progress and flowsheet performance as we move through 2018.”
Standard Lithium CEO, Robert Mintak, commented, “The agreements and business relationships Standard Lithium has struck over the past year have allowed us to fast-track our development timeline. Securing projects with existing permitted brine producers has allowed us access to bulk volumes of raw brine from both of our project areas to conduct process work. Our approach is to intelligently use existing technologies as much as possible and apply project-specific innovations where appropriate; this way, we are not trying to force a technology on the project, but rather to allow the project fundamentals to define the flowsheet.”
Quality Assurance
Dr. Ron Molnar, Professional Metallurgical Engineer (Ontario P.E.# 100111288), is a qualified person as defined by NI 43-101, and has reviewed and approved the scientific and technical information that forms the basis for this news release. Dr. Molnar is independent of the Company.
About Standard Lithium Ltd.
Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills and modern brine processing technologies. The Company is currently engaged in the exploration and resource development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also rapidly conducting resource evaluation on up to 33,000 acres of brine leases located in the Smackover Formation in Southern Arkansas.
Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.
For further information, contact Anthony Alvaro at (604) 240 4793
On behalf of the Board,
Standard Lithium Ltd.
Robert Mintak, CEO & Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.
Readers are cautioned that a “Qualified Person” (as that term is defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects) has not done sufficient work to specify any mineral resource or reserve on the Properties.
MIAMI, FL , March 26, 2018 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (POS), e-commerce and mobile devices, today announces that Mr. Jonathan Fichman has joined Net Element’s board of directors and will serve as a member of the Company’s Audit, Nominating and Governance, and Compensation committees.
Fichman brings over 20 years of strategic domestic and international finance expertise within Fortune 100 companies, is a Bank of America Merrill Lynch veteran, and a former Wall Street analyst. His experience includes FinTech, payments, blockchain, wealth management and banking. Fichman holds a Six Sigma Black Belt accreditation and serves on multiple for profit and nonprofit boards.
Net Element CEO, Oleg Firer, commented, “We are pleased to have Jonathan join our board. He brings extensive, payments, financial, governance and technology experience complementary to our current Board composition and I am confident that he will be a valuable asset to our Company and its shareholders.”
Fichman commented, “Net Element has a great ability to deliver technology-enabled, software-driven solutions that create value beyond just processing payments. The company’s recently announced plans to create a blockchain payments platform and its recently released next generation cloud-based point of sale payments system will both be impactful innovations for the industry. I look forward to joining the board of directors and being a key contributor towards the success of Net Element.”
Since 2013, Fichman has served as a managing director of C-Anax Ventures & Advisory, where he assists early-stage companies with corporate strategy, streamlining operations, and financial analysis. Fichman is also an adjunct professor at Florida International University, where he teaches in the Business School with a focus on international management and entrepreneurship.
From 2005 to 2015, Fichman served as a senior vice president of International Business Strategy & Initiatives at Bank of America Merrill Lynch. From 2003 to 2004, he served as a director of Operations, Procurement and Insurance at the Township of Cherry Hill, New Jersey. From 1999 to 2003, Fichman was a vice president of Strategic Initiatives at Actrade Financial Technologies, where he helped create B2B banking products that were at the forefront of commercial payments. Finally, from 1997 to 1999 he was a Senior Wall Street Analyst. Fichman received his MBA in Finance and Management from the University of Miami School of Business and Bachelor of Arts in Criminal Justice from the George Washington University.
Fichman’s LinkedIn Profile is available at: https://www.linkedin.com/in/jonathanfichman/
The Company’s 8-K filing reflecting the appointment was filed with the Securities and Exchange Commission (SEC) on March 26, 2018 and is available on the SEC’s website.
About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™. In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.NetElement.com.
Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.
Contact:
Net Element, Inc.
1-786-923-0502
media@netelement.com
FREMONT, CA, March 23, 2018 — DPW Holdings, Inc. (NYSE American: DPW) (“DPW” or the “Company“), a diversified holding company, announced that its subsidiary, Super Crypto Mining, Inc. (“SCM”) has entered into an agreement with a U.S. based entity securing the right to 25 megawatts of power in support of SCM’s operations of approximately 20,000 mining rigs at the location.
“We are excited about this new arrangement for many reasons. This not only helps SCM reach our 2018 goals but also provides capacity for future growth. We are proud to be working with a well-respected data facility leveraging efficiencies that result in a symbiotic cost-effective relationship. This is a unique relationship whereby SCM has obtained access to electricity for the miners at costs competitive with global locations, meaning that we can maintain our operations within the U.S. We will have more to share in the coming months specific to the operation as well as “Green Energy” practices that we are employing at the location,” commented Darren Magot, the CEO of SCM.
SCM will be placing at least 2,000 mining rigs at the new location practically immediately. Some of these machines will be supporting our Cloud Mining offering, which we expect will commence on May 1, 2018.
“This is just another example of how Super Crypto Mining is executing on its plans and adding value to the parent company, DPW Holdings,” commented Milton “Todd” Ault III, the Company’s CEO and Chairman. “This new arrangement will allow SCM to build out as it ramps up its operations, dependent on the timing of financing and product availability.”
ABOUT DPW HOLDINGS, INC.
Headquartered in Fremont, CA, DPW Holdings, Inc. is a diversified holding company that, through its wholly owned subsidiary, Coolisys Technologies, Inc., is dedicated to providing world-class technology-based solutions where innovation is the main driver for mission-critical applications and lifesaving services. Coolisys’ growth strategy targets core markets that are characterized by “high barriers to entry” and include specialized products and services not likely to be commoditized. Coolisys through its portfolio companies develops and manufactures cutting-edge resonant switching power topologies, specialized complex high-frequency radio frequency (RF) and microwave detector-log video amplifiers, very high-frequency filters and naval power conversion and distribution equipment. Coolisys services the defense, aerospace, medical and industrial sectors and manages four entities including Digital Power Corporation, www.DigiPwr.com, a leading manufacturer based in Northern California, 1-877-634-0982; Digital Power Limited dba Gresham Power Ltd., www.GreshamPower.com, a manufacturer based in Salisbury, UK.; Microphase Corporation, www.MicroPhase.com with its headquarters in Shelton, CT 1- 203-866-8000; and Power-Plus Technical Distributors, www.Power-Plus.com, a wholesale distributor based in Sonora, CA 1-800-963-0066. Coolisys operates the branded division, Super Crypto Power, www.SuperCryptoPower.com.
Digital Power Lending, LLC, a wholly owned subsidiary of the Company, is based in Fremont, CA, and is a California private lending company dedicated to strategically providing capital to small and middle size businesses for an equity interest in addition to loan fees and interest, www.DigitalPowerLending.com. Excelo, LLC, a wholly-owned subsidiary of the Company, is a national search firm specializing in fulfilling strategic executive, professional and hi-tech placements for businesses delivering world-class services, www.Excelo.com. DPW Holdings, Inc.’s headquarters is located at 48430 Lakeview Blvd., Fremont, California, 94538; 1-877-634-0982; www.DPWHoldings.com. For Investor inquiries: IR@DPWHoldings.com or 1-888-753-2235.
Forward-Looking Statements
The foregoing release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the acquisition and the ability to consummate the acquisition. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at www.DPWHoldings.com.
NEW YORK, March 23, 2018 — iFresh, Inc. (“iFresh” or “the Company”) (NASDAQ:IFMK), a leading Asian American grocery supermarket chain and online grocer, announced today that the company’s management team will present at the 143rd National Investment Banking Association (NIBA) Investment Conference on Tuesday, March 27, 2018 at the Westin New York at Times Square in New York City. Mr. Long Deng, the chairman and CEO of iFresh will be available for one-on-one meetings throughout the conference.
“We are pleased with the opportunity to showcase iFresh and for investors to learn more about our unique business model and strategic development plan,” said Mr. Long Deng, Chairman and CEO of iFresh. “We look forward to meeting with members of the investment community at NIBA and introducing them to our company.”
About iFresh, Inc.
iFresh Inc., headquartered in Long Island City, New York, is a leading Asian American grocery supermarket chain and online grocer. With nine retail supermarkets along the US eastern seaboard (with additional stores in Glen Cove, Miami and Connecticut opening soon), two in-house wholesale businesses strategically located in cities with a highly concentrated Asian population, and six iFresh-managed stores, iFresh aims to satisfy the increasing demands of Asian Americans (whose purchasing power has been growing rapidly) for fresh and culturally unique produce, seafood and other groceries that are not found in mainstream supermarkets. With an in-house proprietary delivery network, online sales channel and strong relations with farms that produce Chinese specialty vegetables and fruits, iFresh is able to offer fresh, high-quality specialty produce at competitive prices to a growing base of customers. For more information, please visit: http://www.ifreshmarket.com/.
About NIBA
Since 1982, The National Investment Banking Association (NIBA) has been a not-for-profit association for the micro-cap and small-cap investment community and has hosted 143 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry. NIBA’s member firms have a 37-year track record of successfully completing thousands of transactions totaling over $15 billion in new capital for emerging growth companies and are responsible for 90% of all IPOs under $20 million.
Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: ifmk@dgipl.com
MONTREAL, March 23, 2018 – Birks, Canada’s leading luxury fine jewelry brand since 1879 has launched the pilot program u·plan in Canada this month. Birks is the first merchant to join the u·plan program in both North and South America, which allows Chinese travelers to download QR Codes containing Birks promotions to their mobile devices.
U·plan is the world’s first open cross-border marketing platform that provides services in the fields of finance, travel and retail. Inspired by new technologies such as Geo-fencing, u·plan focuses on accurate marketing and instant discounts for cross-border consumption, permitting cardholders user friendly and upgrading capabilities.
“It is of great significance to the Birks brand to launch u·plan said Jean-Christophe Bédos, President and Chief Executive Officer of Birks Group. “As an Internationally growing brand, we believe that u·plan will benefit our Chinese customers as we look to align ourselves with these technical capabilities while achieving our expanding objectives.”
Cardholders will have the ability to utilize u·plan by accessing the exclusive QR code gift certificate coupon in the mobile apps of UnionPay International and Chinese issuing banks such as Bank of China and China Merchant Bank. Alternatively, cardholders can receive the gift certificate coupons that could be used at the destination promoted by the apps of UnionPay International’s partner travel agencies at the time of booking airlines or hotels. A reminder to cardholders of these discount coupons will also appear when they are in the vicinity of any Birks location.
Birks looks forward to aligning issuers, acquirers, travel agencies and merchants into the same industry chain with the ultimate focus of making the shopping experience more user-friendly in Canada.
About Birks Group Inc.
The Birks story began four centuries ago in Sheffield, England. The brand truly came to life in 1879 when Henry Birks opened a jewellery boutique in the heart of Montreal, Canada. What began as one man’s dream became an iconic Canadian brand that is now distributed internationally. Birks collections are inspired by Canadian nature and the brand’s rich heritage, offering classic styles with an edgy flair. The Company operates 28 stores under the Birks brand in most major metropolitan markets in Canada. In addition, Birks fine jewellery collections are available through select Mappin & Webb and Goldsmiths locations in the UK, in Mayors stores in the US and at select jewellery retailers across North America. Visit www.birks.com for more information.
March 16, 2018
- Company has added CNBC personality Jon Najarian to its board of directors and various committees
- Net Element is furthering plans for a decentralized blockchain platform
- Company entered 2018 with its strongest-ever balance sheet
Adding some notable star power and financial prowess to its board of directors, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) recently announced the appointment of Jon “Dr. J” Najarian to its board of directors (http://nnw.fm/baYB9). In addition to serving on Net Element’s board, Najarian will serve the company as a member of its audit, compensation, nominating and corporate governance committees.
Najarian, who is a professional investor, money manager and media analyst, is a cast member of the ‘Halftime Report’ and ‘Fast Money’ programs on CNBC and was formerly a linebacker for the Chicago Bears. Among his many accomplishments, he co-founded Investitute LLC, optionMONSTER and tradeMONSTER; founded Mercury Trading; and serves as host of the International ICO Channel. He is additionally featured in the ‘DRJ Report’ on CBOE-TV.
Regarding his appointment to Net Element’s board of directors, Najarian commented that he has been impressed with the company’s technologies, as well as its endeavors to disrupt the payments industry with innovations and value-added services, including recently announced plans for a decentralized blockchain platform.
As Net Element moves forward with its corporate initiatives, Najarian’s considerable expertise in finance, capital markets, cryptocurrency and blockchain will be invaluable to the company. Net Element continues a strong forward march in 2018, supported by the strongest balance sheet the company has ever had, and it is positioned for growth as it continues to execute on promising opportunities.
Hailed as one of Deloitte’s ‘2017 Technology Fast 500™’ and one of the fastest-growing technology companies of 2016 by South Florida Business Journal, Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprises in the United States and select emerging markets. Domestically, the company endeavors to grow transactional revenue by innovating SME productivity services through blockchain technology solutions and Aptito, its cloud-based restaurant and retail point-of-sale solution. On an international level, the company is leveraging its omni-channel platform to offer flexible services to emerging markets with varied banking, regulatory and demographic conditions.
For more information, visit the company’s website at www.NetElement.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
LOS ANGELES, CA / March 23, 2018 / Pain relief, medical imaging, water cleanup, cannabis business, solar and roofing, cloud, blockchain, Facebook; this week on MoneyTV with Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures.
Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.
The television program can also be viewed online immediately at www.moneytv.net.
Featured companies on this week’s program include:
OriginClear, Inc. (OTCQB: OCLN) CEO Riggs Eckelberry celebrated World Water Day and announced a deal in China.
Epazz, Inc. (OTC PINK: EPAZ) Spokesman Matt Chipman spoke of the company’s pending blockchain smart legal contracts product.
ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang discussed the importance of blockchain in the current world economy and the company’s role in the space.
Premier Biomedical, Inc. (OTC PINK: BIEI) CEO William Hartman spoke of the company’s new hemp-based pain relief products with higher concentration levels.
Imaging3, Inc. (OTCQB: IGNG) CEO John Hollister discussed their new board member.
Singlepoint, Inc. (OTCQB: SING) CEO Greg Lambrecht announced the company is branching into the blockchain space.
Solar Integrated Roofing Corporation (OTC PINK: SIRC) President David Savarese discussed another record month looming.
A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.
MoneyTV Executive Producer and Anchor Donald Baillargeon is also the host of MoneyRap Radio, http://www.moneyrap.com and the television program Crowdfund Television, http://www.crowdfundtelevision.com.
MoneyTV with Donald Baillargeon television program, Copyright MMXVIII, all rights reserved. MoneyTV does not provide an analysis of companies’ financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4 month corporate profile with multiple appearances for a cash fee of $11,995.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by Donald Baillargeon, the producer, publisher or parent company of MoneyTV.
Contact:
Donald Baillargeon
info@moneytv.net
949 388 5267
New York, March 22, 2018 — Longfin Corp. (“Longfin” or the “Company”) (LFIN), a global FinTech company, has announced that it has been added to the Russell 2000® Index and the Russell 3000® Index, effective March 16, 2018, as part of Russell’s quarterly additions of companies with recent initial public offerings.
Russell indices are widely used by investment managers and institutional investors for both index funds and as benchmarks for passive and active investment strategies in the U.S. marketplace.
The Russell 3000® Index measures the performance of the largest 3,000 U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell 2000® Index measures performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index.
Venkat S Meenavalli, Chairman and CEO of Longfin, says “We are pleased that Longfin is included in the Russell 2000® Index. We believe that this inclusion reflects the stockholder value we are building and will help increase Longfin’s visibility within the investment community.”
About Longfin Corp.
Longfin Corp (LFIN) is a US-based, global Fintech company powered by artificial intelligence (AI) and machine learning. The Company, through its wholly-owned subsidiary, Longfin Tradex Pte. Ltd, delivers FX and alternative finance solutions to importers/exporters and SME’s. Ziddu.com owned by the company is the only marketplace for smart contracts powered by Consensus Settlement Algorithm on Ethereum blockchain. Ziddu Ethereum ERC20 blockchain Token uses a technology stack in which Smart Contracts run in distributed virtual machines, which in turn run on a Consensus Settlement Algorithm (CSA) providing solutions to warehouse / international trade financing, micro-lending, FX OTC derivatives, bullion finance, and structured products. Currently, the company has operations in Singapore, Dubai, New York and India.
IR Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: lfin@dgipl.com
RAPID CITY, S.D., March 22, 2018 — National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University (“NAU” or the “University”), a regionally accredited, proprietary, multi-location institution of higher learning, today announced the closing of the Henley-Putnam University (“Henley-Putnam”) asset acquisition. The Company also announced strategic operational consolidations aimed at reducing overall operating costs with minimal impact to its student population, which continues to demonstrate a growing preference for online access to education and support services.
Henley-Putnam University Asset Acquisition
The Company announced the closing of the previously announced asset purchase transaction with California-based Henley-Putnam University. Henley-Putnam, the only accredited online university solely focused on strategic security degree and certificate programs, had active student enrollments of 241 as of March 2018 with an additional 43 expected for April. With the closing of the transaction on March 21, 2018, Henley-Putnam’s educational programs became part of NAU’s degree and certificate program offerings. This transaction was subject to customary closing conditions, including approval from the Higher Learning Commission for Henley-Putnam’s programs to be within the scope of NAU’s institutional accreditation immediately upon the closing of the asset purchase transaction.
Strategic Consolidations in 2018
With NAU students increasingly seeking online and mobile access to academic and support services, the University is improving and expanding these services while consolidating certain operations in early 2018. NAU will ensure that students receive quality support services as it consolidates staff previously located at several underutilized locations into existing operations. The consolidations will result in approximately $11.6 million in annual savings for the institution, based on January 2018 expense levels, which will initially be offset by some charges and costs related to existing leases.
Management Commentary
Ronald L. Shape, Ed.D., President and Chief Executive Officer of the Company, stated, “2018 has opened with a busy start as we worked with Zenith Education Group to efficiently transition more than 700 of their students into NAU. The addition of these transfer students and the move to monthly starts had a positive impact on enrollments for the winter 2017-18 term. We believe we will begin to fully realize the benefits of the monthly start in the coming terms as existing and prospective students are able to register for courses and programs with even greater flexibility. With the closing of the Henley-Putnam asset acquisition this month, we have also begun welcoming additional students to NAU and look forward to serving students interested in pursuing careers in the fields of intelligence, counterterrorism, and strategic security.”
Dr. Shape continued, “We remain focused on improving our operational efficiencies while never compromising on our non-negotiables of quality academic programming and regulatory compliance. For over 75 years, NAU has provided students with quality yet flexible academic programming with the necessary support services they need to graduate and to succeed in the workplace after graduation. With our working adult student population exhibiting an increasing preference for NAU’s online course delivery format and remote access to support services, we have worked to optimize delivery of these services by consolidating operations at a number of physical locations, while realigning academic and support staff to better serve the changing needs of our students. We believe the $11.6 million in annual savings we expect from these recent consolidations, as well as our past efforts to better align expenses with revenue and enrollment levels, will enable the Company to move toward positive cash flow generation and better position NAU for steady growth over the long term.”
About National American University Holdings, Inc.
National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-location institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations in several U.S. states. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company’s business. Statements made in this release, other than those concerning historical financial information, may be considered forward-looking statements, which speak only as of the date of this release and are based on current beliefs and expectations and involve a number of assumptions. These forward-looking statements include outlooks or expectations for earnings, revenue, expenses or other future financial or business performance, strategies or expectations, or the impact of legal or regulatory matters on business, results of operations or financial condition. Specifically, forward-looking statements may include statements relating to the future financial performance of the Company; the ability to continue to receive Title IV funds; the growth of the market for the Company’s services; expansion plans and opportunities; consolidation in the market for the Company’s services generally; and other statements preceded by, followed by or that include the words “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions. These forward-looking statements involve a number of known and unknown risks and uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by those forward-looking statements. Other factors that could cause the Company’s results to differ materially from those contained in its forward-looking statements are included under, among others, the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, which the Company filed on August 4, 2017, and in its other filings with the Securities and Exchange Commission. The Company assumes no obligation to update the information contained in this release.
Contact Information:
National American University Holdings, Inc.
Dr. Ronald Shape
605-721-5220
rshape@national.edu
Investor Relations Counsel
The Equity Group Inc.
Carolyne Y. Sohn
415-568-2255
csohn@equityny.com
Adam Prior
212-836-9606
aprior@equityny.com
San Diego, March 22, 2018 — Investors are excited to hear what ChineseInvestors.com, Inc. (OTCQB: CIIX) said about its big moves into the blockchain space on Investor Town Hall Show. ChineseInvestors.com, the premier financial information website for Chinese-speaking investors, commissioned additional revenue streams with ASIC mining machines that generate both Bitcoin and Litecoin.
CIIX is seeing tremendous upside and opportunity for growth in a sector that is expected to grow to $2.3 billion USD by 2021 according to FinTech firm Statista.
The mining operation complements CIIX’s blockchain business strategy by adding to top-line revenue growth. As the company begins educating its subscribers on trading crypto on its other Chinese-investor-targeted media platform, NewCoins168.com, the plan is cross-pollinating new crypto revenue streams into its existing products and services. On May 1st investors will be able to enroll in online cryptocurrency trading academy that CIIX is adding to NewCoins168.com’s platform to learn about trading Bitcoin futures, alt coins, technical analysis and investing in ICOs.
ChineseInvestors.com is proud to provide Chinese-speaking investors here in the US the knowledge to take advantage of the cryptocurrency upside potential, while educating them on the risks and rewards.
Wang says the goal is to double or triple the company’s revenue every year by making more synergistic investments into revenue streams that add more value to the company by creating subscription products called “Cryptocurrency VIP Club.” He explains more about it in the interview.
Watch the full interview here: https://www.youtube.com/watch?v=TUE_btgugDA
About Investor Town Hall, LLC
Investor Town Hall, LLC is a media company that covers emerging-growth companies in capital markets, equity crowdfunding and cryptocurrency markets. Investor Town Hall Show interviews CEOs, executives, venture capital firms, technical analysts and thought leaders in public markets and blockchain technology space. Investor Town Hall Show, all rights reserved. Investor Town Hall Show does not provide company analysis and is not soliciting to purchase or sell securities of companies, nor offering any financial recommendation of featured companies and its stocks or its digital tokens. Information discussed herein is provided by companies and should not be taken as financial advice. Investor Town Hall Show provides multimedia content and distribution and does not accept company stock as payment for services, nor currently hold any positions in any company that is publicly traded in the United States.
www.Investortownhall.com
About ChineseInvestors.com (OTCQB: CIIX)
Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.
For more information visit ChineseInvestors.com
Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom
Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh
Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;
https://www.facebook.com/Chineseinvestors.com.english
Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Source:
Investor Town Hall, LLC and ChineseInvestors.com, Inc.
Contact:
Daniel Wong
Dan@investortownhall.com
858-381-4622
DORAL, Florida, March 22, 2018 — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, is pleased to announce its membership in the 16th cohort of Défi Montréal, the largest innovative business acceleration program in Quebec, to accelerate the development and growth of the Company.
Défi Montréal founder Martin Duchaîne is a renowned venture capitalist and leader in business financing and development. In his 20-year career he has advised or assisted more than 900 entrepreneurs, and has developed an exceptional business network that includes leaders from the business community. His vision, combined with the strength of his Défi Montréal program and industry relationships, will accelerate the development and commercialization of new ETST products.
“I have known Martin Duchaîne for many years and finally the time has come for us to work together. I am proud to have a mentor with this track record in business development and product positioning. His experience and dedicated coaching means we won’t leave anything to chance,” states ETST CEO and Chief Scientific Officer Michel Aubé PhD.
Through its participation in Défi Montréal, ETST has found key individuals to help finance and operate its second distribution facility, and has also retained a consulting engineer to polish the manufacturing plan for the soon-to-market MSN-2 medical device (http://nnw.fm/3vHwU). Leveraging new knowledge capital, ETST will develop a business model to be copied overseas by partnered companies.
“We are proud to welcome Earth Science Tech as member of Défi Montréal,” says Duchaîne. “We appreciate Dr. Aubé and his ability to learn from the success of our best tech entrepreneurs. We are confident he will accelerate the growth of ETST in Canada and many other countries with their existing products and the new, exciting ones they are preparing to launch.”
Duchaîne is also the co-founder of Québec Angels, and has served as general manager of Techno Montréal, which brings together more than 2,700 companies, institutions and parapublic organizations in the Greater Montreal’s information and communications technology cluster.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.
To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com
About Earth Science Pharmaceutical
Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.EarthSciencePharmaceutical.com
About Cannabis Therapeutics
Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.CannabisThera.com
About KannaBidioiD
KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
To learn more please visit: www.KannaBidioiDInc.com
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Dave Demarest
305.546.7640 Office
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, Chief Operating Officer
305.615.2118 Office
The industry surrounding blockchain technology has certainly helped to drive more interest from investors. Fortune 500 companies, trillion-dollar banks, and some of the largest investors of our time have signaled fresh opportunity in new breakthroughs within this market. Where the topic was introduced through the boom in things like bitcoin and Ethereum, blockchain technology has become far more valuable that just a means to track cryptocurrency transactions.The fact of the matter is this: hundreds of billions of dollars have been and continue to be pushed into this market with investors getting immediate and direct exposure to things like blockchain technology by putting their money into the market; not into the cryptocurrency market but directly into the stock market. In fact, after the initial crypto boom, most of the attention has shifted toward the technology side of this industry versus the currency side. The result has been clear, breakthrough technologies that aim to change countless other industries across the globe.
Block One Capital (BKPPF) (BLOK.V), for instance is making the move take full advantage of blockchain technology by executing through its strategic investments already in the works. The company has simplified the process through an offering of class leading investments across multiple segments of this new industry.
Turn Back The Clock And Learn From Past Trends: New Focus Is On Blockchain Infrastructure
Investors have already seen early opportunity with many stocks that have made previous moves due to the progress and excitement surrounding blockchain technology. Eastman Kodak Company (KODK) is most notably built on the imaging industry but had found incredible success in its recent diversification strategy. Kodak and WENN Digital Inc. announced the launch of the KODAKOne image rights management platform. The platform itself was built to empower photographers and agencies to take greater control in image rights management.
Utilizing blockchain technology, the company has expressed that KODAKOne will create an encrypted, digital ledger of rights ownership for photographers to register both new and archive work that they can then license within the platform. Following several related announcements, share of KODK managed to soar from under $3 to as high as $13.28 within a matter of weeks.
In line with that trend, Net Element’s (NETE) blockchain-focused business also managed to attract a diverse and very bullish sentiment all focused on a decentralized ecosystem acting as a framework for value-added services. Net Element had explained that the ecosystem could connect merchants and consumers directly utilizing blockchain technology.
It also would be capable of increasing the speed and efficiency of transactions made through the Company’s processing, settlement and services ecosystem. Previous to its diversification strategy into blockchain technologies, Net Element was trading around $2.50 before running to highs of over $33.50. Shares of the company saw a strong pull back but are still trading over 3.5 times higher than they were in December of 2017.
With facilities in northern Sweden and WA State, MGT Capital Investments, Inc. (MGTI) ranks as one of the largest U.S. based Bitcoin miners. Though the company hasn’t taken the leap to focus entirely on blockchain technology, the blockchain itself is a vital part of the entire cryptocurrency ecosystem. Further, the Company continues to execute on an expansion model to grow its assets materially.
The company recently sold of its cyber security product, Sentinel to focus entirely on its cryptocurrency operations. Though cyber security and crypto front man, John McAfee has decided to leave the company as Chief Cybersecurity Visionary, he remains a “major stakeholder”.
“I would like to thank Steve, Rob Ladd and the entire board for giving me the opportunity to return to corporate life, but I am very happy with my decision. I am looking forward to toiling in obscurity as the world’s foremost authority of all things cyber and crypto! In all candor, the past two years have been action-packed and productive, and I want to thank all shareholders for their support. I leave MGT in much stronger condition than when I arrived and remain a major stakeholder,” said McAfee in a recent press release.
MGT was trading at levels that were under $1.50 late last year before jumping to over $8 per share during its expansion into the blockchain technology space. Obviously the previous winners within this industry have come and gone, but now that investors have become more informed, they are better prepared to read the tea leaves for the next wave of potential within the space.
The Billionaire Effect
The usual case for any “early boom” industry has been traditionally driven by highly speculative and generally high-risk investors during the first wave of interest. But as far as blockchain technology is concerned, we aren’t just seeing high risk traders coming into the market, we are also seeing experienced and long standing financial figure heads taking aim at companies involved in the blockchain space.
George Soros and his Quantum Fund, for example has already been the focus of several articles that highlighted his investment into Overstock.com (OSTK) specific to the company’s blockchain platform & plans to further advance the technology.
Patrick Byrne, CEO of Overstock confirmed that a significant part of the investment from George Soros would be used to fund blockchain work undertaken by the company. He added that a cool $20 million would be used to fund DeSoto Inc., which is a joint venture in blockchain property venture. Byrne also expressed that as the company develops the blockchain companies and blockchain applications, its retail business would be significantly valuable in bringing traffic and awareness to its blockchain properties that the company expects to grow.
Furthermore, staunch opponent of bitcoin cryptocurrency, Jamie Dimon of JPMorgan is actually bullish on the utilization of blockchain technology. The J.P. Morgan CEO sees promise in blockchain going as far to state, “The Blockchain is a good technology, we actually use it, and it would be useful for a lot of things….JP Morgan moves $6 trillion around the world every day. We don’t do it in cash. It’s done digitally.”
There is even a dedicated portion of the company’s website dedicated to blockchain technology and how it will benefit the public.
“The Blockchain Center of Excellence (BCOE) leads efforts for applications of distributed ledger technology (DLT) within J.P. Morgan. We are exploring blockchain use cases and piloting solutions across business lines. We are active in the blockchain ecosystem: developing technology, investing in strategic partnerships, and participating in cross-industry consortia.”
Diversification to Expand Revenue Generation
In the case of Block One Capital (BKPPF), the company looks to deliver on core divisions that are focused on the advancements that blockchain technology has achieved.
1. Finzat Block LLC: A Blockchain Solution for the US Mortgage Industry
Block One has acquired 40% of Finzat Block LLC, a New York based mortgage blockchain company aiming to streamline and digitize the US mortgage market using innovative blockchain applications to create a system which is Simple, Auditable, Fault-tolerant and Efficient (SAFE).
Finzat has named Michael W. Moore as the company’s Chairman. Mr. Moore is a recognized leader in mortgage finance and investment and risk management. During his 15 years as the senior-most financial executive with the Chicago Federal Home Loan Bank, he was the co-developer of Mortgage Partnership Finance, a mortgage origination platform whereby Federal Home Loan Bank members participate in a unique risk sharing arrangement with their respective FHLB optimizing benefits for both parties.
Since the mortgage industry is a $9.9 trillion sector Block One Capital can utlize its Finzat arm to lead the transformation of the US mortgage collateral and compliance marketplace by applying advanced blockchain principles. Obviously like many, the mortgage industry is ripe for blockchain solutions to drive efficiency, reduce costs, streamline workflows and improve the customer experience.
2. CUIPO: A Social Initiative for Rainforest Preservation
CUIPO is a London UK based technology business harnessing the power of blockchain to digitize and democratize the purchase and preservation of natural land assets. They specializes in technologies and infrastructure created to save and protect endangered lands. They do this by the gamification of online conservation efforts, achieved by using a patented virtual grid system and tokenization method, one square meter at a time. CUIPO’s revenue streams will be: product licensing, educational gift card products, global event and festival sponsorship opportunities and creation and management of Corporate Social Responsibility services for medium to large enterprises. Though this may seem like a simplistic or minor business arm, the spending that goes into environmental preservation is immense and thus creates an open opportunity for blockchain technology intervention and further the accountability that comes along with it.
Access To Capital Is Key For Growth
Block One increased has been able to increase its financial strength through key capital raises that totaled $10 million to this point. This particular raise was conducted at $1, which is currently higher than where the market is right now. As of March 2018, shares of Block One are trading below this level with a price range of roughly $0.58-$0.63. It should also be noted that in relation to the raise, all securities issued are subject to a holding period that lasts well through the month of April.
“We are very pleased to have completed a successful oversubscribed financing in such a short period of time. Our model identifying early stage, high growth opportunities with the best in class management has resonated with the investment community. We remain focused on the business plan execution for our two recently announced investments and also the potential in our growing pipeline of additional investment opportunities,” explained David Berg who is a current director of Block One.
Conclusion
Don Tapscott, author of “The Digital Economy has said, “The first generation of the digital revolution brought us the Internet of information. The second generation — powered by blockchain technology — is bringing us the Internet of value: a new platform to reshape the world of business and transform the old order of human affairs for the better.”
Even the former US Treasury Secretary, Larry Summers has stated that blockchain technology will be a game changer, “I’m reasonably confident … that the blockchain will change a great deal of financial practice and exchange.”
For companies entering the next phase of blockchain technology expansion, Block One Capital (BKPPF) (BLOK.V) has been a clear example of how companies are working to meet the growing demand for industry evolution. Though this is still a young and early stage industry, it isn’t just high-risk day traders taking a shot at this opportunity either.
As noted previously, there is obvious and growing interest coming from some of the leading financial figureheads involved with the stock market; George Soros and Jamie Dimon being a few notable names. Timing for this new industry could mark a profound turning point where new technology like blockchain ends up pushing the limits of traditional marketplaces like mortgage and housing to new and exciting bounds.
CONTACT: info@coinchainmarket.com
NOT AN OFFERING / DISCLAIMER
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither CoinChainMarket nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. CoinChainMarket.com is owned by JSG Communications & expects to be compensated up to $500,000.00 by Block One Capital Inc. for a period beginning March 3, 2018 and ending September 5, 2018, to publicly disseminate information about (BKPPF). We may buy or sell additional shares of (BKPPF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Full Disclaimer Click Here
SOUTH SAN FRANCISCO, Calif., March 21, 2018 — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has planned a meeting to review the Company’s New Drug Application (NDA) for plazomicin for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and bloodstream infections (BSI) due to certain Enterobacteriaceae in patients who have limited or no alternative treatment option.
In the NDA acceptance letter, the FDA stated that it was planning to hold an advisory committee meeting and the Company has announced today that the meeting is planned to take place on May 2, 2018. The target action date under the Prescription Drug User Fee Act (PDUFA) is June 25, 2018.
About Plazomicin
The Plazomicin NDA is supported by data from both the EPIC and CARE clinical trials which evaluated the safety and efficacy of plazomicin in patients with serious infections caused by gram-negative pathogens, including extended-spectrum beta-lactamase (ESBL) producing and carbapenem-resistant Enterobacteriaceae (CRE). The FDA granted Breakthrough Therapy designation for plazomicin for the treatment of BSI caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Breakthrough Therapy designation was created by the FDA to expedite the development and review of drugs that target serious or life-threatening conditions. Plazomicin has also received Qualified Infectious Disease Product designation from the FDA which provides incentives for the development of new antibiotics, including priority review and an additional five years of market exclusivity.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program has been funded in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. The Company’s second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen’s expectations regarding potential regulatory approval and label of plazomicin, Achaogen’s plans regarding an application for marketing authorization in the European Union, plazomicin’s potential to address certain MDR infections, plazomicin’s potential to treat serious bacterial infections, including those due to CRE and ESBL-producing Enterobacteriaceae and Achaogen’s pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the uncertainties of having an NDA accepted by the FDA, the risks and uncertainties of the regulatory approval process; the risks and uncertainties of commercialization and gaining market acceptance; the risk when bacteria will evolve resistance to plazomicin or C-Scape; Achaogen’s reliance on third-party contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen’s patents or proprietary rights; and the risk that Achaogen’s proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen’s business in general, see Achaogen’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
arr@lifesciadvisors.com
Media Contact:
Denise T. Powell
Red House Consulting, LLC
dpowell@achaogen.com
Palm Beach, FL – (March 21, 2018) — The interest for digital currencies appears to be rising again of late and in turn, cryptocurrency mining operations are starting to pick up steam as the currency once again attempts to assert itself as a mainstay in the global economy. Although cryptocurrency mining has been in existence for 10 years, the momentum is currently building rapidly as the practice becomes more mainstream. Multiple private corporations have engaged in expanding operations to both acquire and enhance cryptocurrency mining methods as the market cap for bitcoin alone approaches $160 billion. In turn, blockchain technologies are becoming increasingly essential to maximize cryptocurrency mining potential, as well as to bolster security against enhanced security risks. The headlines in the digital currency market include leaders in the space acquiring new equipment to maximize their cryptocurrency mining efforts, as well as an overall update on the state of blockchain. Active stocks in the markets include: DMG Blockchain Solutions Inc. (TSX-V:DMGI) (OTC:DMGGF), HIVE Blockchain Technologies Ltd. (OTC: HVBTF) (TSX-V: HIVE), Long Blockchain Corp. (NASDAQ: LBCC), Global Blockchain Technologies Corp. (OTC: BLKCF) (CSE: BLOC), Marathon Patent Group Inc. (NASDAQ: MARA).
DMG Blockchain Solutions Inc. (TSXV:DMGI.V) (OTC:DMGGF) BREAKING NEWS: DMG Blockchain Solutions Provides Sales Update, and Detailed Description of Strategic Partnerships with achievements and operational highlights that include:
• 2,650 Mining Rigs Sold: MAAS allocated 4MW of power sold out in just the past few months
• Power Update: DMG expects an additional 40MW ready for Spring 2018
• Bitcoin Mining: Launching what could be the largest industrial bitcoin mining complex in North America with power capacity of up to 85 megawatts
• Blockseer and AI: Carefully managed M&A plan underway with the acquisition of leading Silicon Valley-based artificial intelligence (AI) and Blockchain company, Blockseer
• Key partnerships that can be catalysts for growth and margin expansion (Bitmasters, Foreside Financial, Mogo, Emerald Therapeutics, Element Fleet Management, D-Link, Primary Engineering and Cannachain)
• More than $35 million raised since November 2017 with institutional ownership of more than 20%
DMG Blockchain Solutions, a diversified blockchain and cryptocurrency company, announced today that it has sold out it’s current capacity of 2,650 mining rigs for its cryptocoin Mining-as-a-Service (MaaS) business. Under the unique MaaS business model, customers purchase the mining rigs and receive all the bitcoin directly and DMG provides hosting and management services – a stable and predictable revenue stream. Additionally, the company’s Q1 operational milestones include construction of a new 85 megawatt mining facility, the acquisition of A.I. leader Blockseer, and signed agreements with key partners including D-Link, Primary Engineering, Emerald Therapeutics, Mogo, Foreside Financial, and Bitmasters.
DMG CEO Dan Reitzik commented, “This is the first quarterly report for our shareholders and the first of many to come. We continue to provide our shareholders with opportunities other crypto players do not see, or are unable to execute on, due to our experience and relationships built over several years in the industry. DMG is not only establishing itself as the leader in crypto mining but in blockchain and AI platform development with our recent acquisition of Blockseer. Our pipeline is strong and exciting and few have it. In fact, market weakness has created more opportunities for DMG as power providers are getting more educated as to who they want to deal with. We thank our investors and customers for all their support to date.” Read this and more news for DMG Blockchain Solutions at http://www.marketnewsupdates.com/news/dmgi.html
Additional industry related developments from around the markets:
HIVE Blockchain Technologies Ltd. (OTC: HVBTF) (CDNX: HIVE.V) last week the company announced it has applied for listing of an aggregate of 48,830,150 common share purchase warrants on the TSX Venture Exchange as a supplemental listing. The warrants were issued pursuant to private placements of the company that closed on Nov. 14, 2017, Dec. 18, 2017, and Dec. 29, 2017. Subject to TSX-V approval, the warrants will commence trading on the TSX-V under the symbol HIVE.WT concurrently with the expiry of each applicable four-month-and-a-day hold period attached to such warrants. Hive expects 12,322,250 of the warrants to be listed on March 15, 2018, 15,873,100 of the warrants on April 19, 2018, and the remaining 20,634,800 warrants on April 30, 2018. Hive Blockchain Technologies is a growth-oriented, TSX Venture Exchange-listed company, building a bridge from the blockchain sector to traditional capital markets.
Long Blockchain Corp. (NASDAQ: LBCC) recently announced it has closed on a strategic investment in Stater Blockchain Limited (“Stater”), a technology company focused on developing and deploying globally scalable blockchain technology solutions in the financial markets. Stater’s wholly-owned subsidiary, Stater Global Markets, is a Financial Conduct Authority (FCA) regulated brokerage that facilitates market access across multiple instruments including spot FX, exchange traded futures and contracts for difference (CFDs). “As previously announced, we had been in discussions to merge with Stater. As the expiration date of the letter of intent approached, both parties agreed that a minority investment with dual board representation would allow us to immediately formalize our partnership while maintaining our respective autonomy,” stated Shamyl Malik, Chief Executive Officer of Long Blockchain. “We are pleased to announce this strategic investment, which further demonstrates our shared commitment to building blockchain technologies.”
Global Blockchain Technologies Corp. (OTC: BLKCF) (CSE: BLOC.CN) recently announced it has closed the acquisition of Coinstream Mining Corp., previously announced on Feb. 13, 2018, by way of a three-cornered amalgamation. Under the terms of the definitive acquisition agreement, the company acquired 100 per cent of Coinstream and assumed all of its existing assets and underlying agreements at present, including The Manitoba joint venture facilities totalling 50 megawatts of capacity, with 35 megawatts of capacity available immediately. Global Blockchain’s subsidiary will supply cryptocurrency mining units on the basis of a 70/30 split in favour of Global Blockchain. Distributed Mining would allow anyone with a connected device to download and install a software packet, giving the user access to optimized cryptocurrency mining. The distributed mining platform will be able to optimize for variable mining requirements, and its design is particularly well suited for gaming consoles, of which there are over 100 million currently connected units. Gaming consoles contain stronger processing power than that found in typical laptop/desktop computers, making them the perfect environment to deploy the distributed mining platform as individuals are able to put their resting consoles to work, earning them valuable cryptocurrency tokens.
Marathon Patent Group Inc. (NASDAQ: MARA) recently announced that it has commenced bitcoin mining at its new facility in Quebec. On February 8, 2018, the Company announced it had purchased 1,400 Bitmain Antminer S9 miners (“Antminer S9s”) and on February 15, 2018 the company announced it had leased 26,700 square feet of data center space in Quebec, Canada. The Company is pleased to announce the completion of its installation and the commencement of operations which are expected to utilize approximately 2.0 MW and deliver approximately 19 Ph/s of ASIC mining capacity. The Antminer S9s are presently mining Bitcoin, but are able to mine other digital assets/cryptocurrency using the SHA256 algorithm.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty nine hundred dollars for news coverage of the current press release issued above by DMG Blockchain Solutions Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com – +1(561)325-8757
MENLO PARK, Calif., March 21, 2018 — Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m. Eastern Time on Tuesday, March 27, 2018.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/needham86/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com
VANCOUVER, British Columbia, March 21, 2018 — Subject to receipt of all requisite regulatory approvals, Victory Square Technologies Inc. (“Victory Square” or the (“Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) will acquire 49% percent of all issued and outstanding shares of Flo Digital Inc. (“Flo”), for $1,000,000 CAD in total consideration (the “Purchase Price”). In addition to the equity investment, Victory Square will be providing a $300,000 CAD convertible note. The note will convert upon a minimum financing of $1,000,000 CAD at a 20% discount to the issue price.
Pursuant to a definitive subscription agreement executed between the Company and Flo (the “Subscription Agreement”), the Purchase Price will be paid and satisfied by the Company through the issuance of 446,428 common shares in the capital of the Company (the “Consideration Shares”) to Flo at a deemed issue price of $2.24 per Consideration Share. The deemed issue price represents the closing price of the common shares of the Company on the Canadian Securities Exchange at the end of trading on March 20, 2018, the trading day preceding this news release announcing the acquisition. The Consideration Shares shall be subject to resale restrictions, which permit 8% of the Consideration Shares to be eligible to be free trading four months from the date of issuance to satisfy the statutory hold period and a further 8% every three months thereafter until the final balance of Consideration Shares is eligible to be free-trading in approximately three years’ time. The Subscription Agreement also contains standard representations, warranties and covenants for transactions of this nature.
Flo provides immersive and interactive VR ad experiences that aim to completely immerse the viewer into the brand experience, allowing them essentially to become the star of the ad. The Flo VR AD Tech platform has an active user network of 200M monthly viewers throughout North America. The VR network spans across several platforms, including HTC VIVE, Google Cardboard, Google Daydream, IOS, Android and Web VR. Flo offers a wide range of VR / AR ad formats that enable websites and app publishers to monetize their content, by seamlessly launching VR / AR ad experiences to their viewers, via the Flo SDK.
For example, one of Flo’s latest VR / 360 Video experiences for Chrysler Canada allows the user to virtually test drive the All New Dodge Challenger. Flo will be working with Chrysler Canada to distribute this 360-experience on-site at various National Chrysler events. Flo will also be distributing the experience through the Dodge Challenger 360 Experience –
https://drive.google.com/file/d/17bWLNKvLgyk_UnGYOXWSgB6tTdqtUz49/view?usp=sharing
“We are pleased to announce our investment in Flo Digital Inc., an innovative virtual and augmented reality company focused on disrupting the way advertisers connect with their end customers,” said Shafin Diamond Tejani, CEO of Victory Square Technologies. “Flo Digital has a proven track record of providing cutting edge and immersive VR/AR experiences to leading brands that include Chrysler Canada, Warner Bros., and Rogers Wireless to name a few. It is this caliber of customers and execution that makes the entire team at Victory Square eager to work with Flo Digital on their next stage of growth.”
“This represents another investment in the VR/AR industry and further illustrates our thesis that blockchain technology will disrupt the existing landscape in ad-tech and ultimately change the way brands will connect with their customers,” continued Tejani. “As Flo rolls out the first ever augmented reality blockchain solution as we anticipate rapid adoption from existing customers and a high degree of interest from new brands.”
Flo is currently building out the first ever Cause Related, Virtual Reality and Augmented Reality Blockchain – Ad tech platform. Flo will tie in a charitable component on every ad campaign, giving back a percentage of revenue from each campaign to select causes around the globe, being mindful of the cause-related premise, which is to help others.
“We are both excited and incredibly grateful to announce our new partnership with Victory Square Technologies, a leading Canadian venture builder,” said Roger Perry, CEO and Founder of Flo Digital Inc. “Victory Square’s passion for philanthropy, their undeniable proven track record in investing and exiting innovative companies, and their extensive experience in the blockchain space makes them the perfect collaborative partner for Flo. In the coming year we plan to work side by side with Victory Square in building the first ever Cause Related, Virtual Reality and Augmented Reality Blockchain.
For further information about the Company, please contact:
Investor Relations Contact – Prit Singh
Email: prit@victorysquare.com
Telephone: 905-510-7636
Media Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-928-6066
ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.
ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.
FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
- Prothena to receive a $100 million upfront payment and a $50 million equity investment by Celgene, with potential license payments and regulatory and commercial milestones, plus additional royalties on net sales from licensed programs
- Collaboration focuses on preclinical programs targeting proteins implicated in several neurodegenerative diseases, including tau, TDP-43 and an undisclosed third target
- Prothena to host an investor conference call and webcast today at 5:00 PM ET
DUBLIN, Ireland, March 20, 2018 — Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration with Celgene Corporation (NASDAQ:CELG) through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases. The multi-year research and development collaboration is focused on three proteins implicated in the pathogenesis of several neurodegenerative diseases, including tau, TDP-43 and an undisclosed target. For each of the programs, Celgene has an exclusive right to license clinical candidates in the U.S. at the investigational new drug (IND) filing and if exercised, would also have a right to expand the license to global rights at the completion of Phase 1. Following the exercise of global rights, Celgene will be responsible for funding all further global clinical development and commercialization. Under the terms of the collaboration, Prothena will receive a $100 million upfront payment and a $50 million equity investment by Celgene, plus future potential exercise payments and regulatory and commercial milestones for each licensed program. Prothena will also receive additional royalties on net sales of any resulting marketed products.
“Prothena has a legacy of innovation in neuroscience and a team with a deep understanding of biological approaches that target protein misfolding disorders. Our collaboration leverages each company’s core expertise in protein homeostasis and protein clearance to target proteins that are the underlying cause of many neurodegenerative and orphan diseases. The programs we have chosen to collaborate on have the potential to provide foundational assets from which we can build new therapeutic approaches to these currently untreatable neurological disorders” said Richard Hargreaves, PhD, Corporate Vice President Neuroscience and Imaging for Celgene.
“We are excited to be working with Celgene, a leading global biopharmaceutical company with deep expertise in targeting critical biological pathways involved in protein homeostasis and an extensive track record of successfully bringing forward innovative new therapies based on this biology,” said Gene Kinney, PhD, President and Chief Executive Officer of Prothena. “As we build our pipeline of novel therapies across the neuroscience and orphan disease categories, this collaboration provides Prothena the opportunity to work with a premier scientific partner and the resources and flexibility to advance these programs while continuing to expand our proprietary discovery activities and further supports our efforts to deliver a diversified pipeline of therapies to alter the course of devastating diseases.”
Collaboration Agreement Overview
Prothena will receive an upfront payment and equity investment, and is eligible to receive exercise payments and regulatory and commercial milestones, plus additional royalties on net sales based on the following collaboration deal terms:
- Prothena will receive an upfront payment of $100 million
- Celgene will make a $50 million equity investment in Prothena by subscribing to approximately 1.2 million of Prothena’s ordinary shares at $42.57 per share
- For programs reaching commercialization, Prothena will receive tiered royalties on net sales
The targets encompassed in this collaboration are implicated in the pathogenesis of several neurodegenerative diseases for which there are no current disease modifying therapies, including the following:
- Tau, a protein implicated in diseases including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE) and other tauopathies. Prothena has identified antibodies targeting novel epitopes on the tau protein with the ability to block misfolded tau from binding to cells and to inhibit cell-to-cell transmission, preventing downstream functional toxic effects.
- TDP-43, a protein implicated in diseases including amytrophic lateral sclerosis (ALS) and the most common subtype of FTD, behavioral variant FTD (bvFTD), a proportion of AD and other TDP-43 proteinopathies. Prothena has generated antibodies that target multiple epitopes on the TDP-43 protein and is using proprietary in vitro screening methodology to select those that may be the most potent and efficacious in inhibiting toxicity and cell-to-cell transmission of misfolded TDP-43 species.
Citi is acting as financial advisor to Prothena and Latham & Watkins LLP is acting as legal counsel to Prothena. Morgan Lewis is acting as legal counsel to Celgene.
Investor Conference Call and Webcast Details
Prothena management will host a conference call and webcast to discuss the collaboration today, March 20, at 5:00 PM ET. The conference call and webcast will be made available on the Company’s website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the conference call and webcast, a replay will be available on the Company’s website for at least 90 days.
To access the conference call via dial-in, please dial (877) 887-5215 (U.S./Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 8469456. A replay of the call will be available until March 27 via dial-in at (855) 859-2056 (U.S./Canada toll free) or (404) 537-3406 (international), Conference ID Number 8469456.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Prothena’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic approaches against targets such as tau, Aβ (Amyloid beta) and ALECT2 where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company’s website at www.prothena.com.
Forward-looking Statements by Prothena
This press release contains forward-looking statements by Prothena. These statements relate to, among other things, potential future payments and royalties we might receive under the collaboration with Celgene; our ability to advance a growing pipeline of novel therapies in the neuroscience and orphan disease categories; our ability to advance any of the programs that are the subject of the collaboration with Celgene; the potential of those programs to lead to new therapeutic approaches to currently untreatable neurological disorders; the potential targeting of novel epitopes on misfolded forms of tau protein and LECT2 protein; and the capabilities of our proprietary in vitro screening methodology for TDP-43. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the “Risk Factors” sections of Prothena’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2018 and Prothena’s subsequent Quarterly Reports on Form 10-Q filed with the SEC. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena’s expectations.
Contact:
Ellen Rose, Head of Communications
650-922-2405
ellen.rose@prothena.com
SAN DIEGO, March 20, 2018 — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option to purchase up to an additional 1,125,000 shares of its common stock. All of the shares are being offered by Arena. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Citigroup and Leerink Partners are acting as joint book-running managers for the offering. Cantor, Credit Suisse and RBC Capital Markets are also acting as joint book-running managers. Guggenheim Securities and JMP Securities are acting as co-managers for the offering.
The shares of common stock described above are being offered by Arena pursuant to a shelf registration statement filed by Arena with the Securities and Exchange Commission (SEC) that became automatically effective on July 11, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or by email at syndicate@leerink.com; or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com; or from RBC Capital Markets LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Arena Pharmaceuticals
We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across multiple therapeutic areas. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. Our three most advanced clinical programs are: ralinepag (APD811), which we are currently preparing for a Phase 3 program for pulmonary arterial hypertension; etrasimod (APD334), for which we are planning a Phase 3 program for ulcerative colitis and are continuing to study for other immune and inflammatory conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn’s disease. In addition, we have collaborations with the following pharmaceutical companies: Everest Medicines Limited (ralinepag and etrasimod in Greater China and select countries in Asia), Axovant Sciences GmbH (nelotanserin – Phase 2), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ®/BELVIQ XR® – marketed products).
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “plan,” “believe,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Arena’s expectations with respect to the completion, timing and size of the proposed public offering. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering; and those factors disclosed in Arena’s filings with the SEC, including our Form 10-K for the year ended December 31, 2017. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
March 20, 2018
NetworkNewsWire Editorial Coverage: The proposed legalization of recreational cannabis this year is expected to mean huge growth in the Canadian cannabis sector, and companies are preparing to make the most of it. Choom™ Holdings, Inc. (CSE: CHOO) (OTCQB: CHOOF) (CHOOF Profile) is creating a premium lifestyle brand backed by an integrated supply chain, while Hiku Brands Co. Ltd. (CSE: HIKU) (OTC: DJACF) (DJACF Profile) is applying for the final license to sell its handcrafted cannabis flower. Medical marijuana producer Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF) has obtained outside funding to explore the potential of cannabis-infused soft drinks, and Aphria, Inc. (TSX: APH) (OTCQB: APHQF) is using a strategy of collaboration and targeted investment to boost its cannabis production resources. For consumers concerned about the quality of their smokes, ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) (ABCCF Profile) is using a specially developed technique to ensure a consistently high-grade, premium organic cannabis.
Recreational Cannabis Coming to Canada
The imminent legalization of recreational cannabis in Canada is expected to lead to a huge boom in the broader cannabis industry. Even without recreational legalization, around 5 million Canadians consumed marijuana in 2017. According to Statistics Canada, 90 percent of the nearly $6 billion was spent for illegal, nonmedical purposes—suggesting that when the law changes, even more Canadians will give it a go. Canadians spend nearly as much on cannabis as on wine, and when recreational cannabis use gets the green light, those profits are expected to shift from criminal gangs and street dealers to businesses and high street vendors. The potential for profit is huge, with recreational cannabis forecast to quickly outpace the medical market.
The activities of cultivators taking steps to expand their production capabilities indicate faith in the massive consumer demand for retail cannabis. While the medical market established the roots of Canada’s cannabis industry, first-comer recreational brands have a chance to take dominant places in this newly emerging sector.
A Relaxing Brand for a Relaxing Industry
For many consumers, the appeal of cannabis is its relaxing properties. This is the angle that Choom Holdings (CSE: CHOO) (OTCQB: CHOOF) its targeting with its carefully crafted recreational cannabis brand.
Though based in British Columbia, Choom has built its brand around a very different part of the Americas. By evoking the spirit of Hawaii, the company aims to tap into the ethos of surf, sand and chilled times for which the island is known. In fact, the organization’s name is drawn from the slang of 1970s Hawaii and the story of a group of friends who loved to smoke weed—or “choom.”
That youthful appeal is part of Choom’s branding with deliberate imagery designed to attract consumers with a relaxed and laidback vibe. Recreational cannabis companies, like any company focused on recreational products, will need to tap into the disposable incomes of 20-somethings as both tastemakers and a source of profit. This approach may help the brand lay claim on a solid chunk of an expected $6 billion market.
Big Ambitions for a Big Market
Choom is going big on investment in the recreational cannabis market, and it’s easy to see why. As cited by the Financial Post, Canaccord Genuity forecasts that there will be an estimated 3.8 million recreational and 500,000 medical cannabis users in Canada by 2021. That’s more than eight times as many users as exist in the current already profitable and purely medical market.
This growth is predicted to create an industry significantly larger than the $5 billion industry in spirits and almost as large as the $7 billion wine industry. Choom’s aim is to become a leading retailer within that industry. The company’s early start, which includes years of planning and preparing branding, facilities and business strategy, could put it in a strong position to reach that goal.
Choom’s tactic is to position itself as a purely recreational brand with a line of premium products. It will be a fully integrated company positioned to scale up as needed. As part of this, it intends to develop and acquire positions, brands and products focused specifically on this market. This approach provides contrast with competitors emerging from the medical market.
Building a Strong Production Base
License and production assets are a critical part of this strategy, allowing Choom to quickly grow in line with the market.
The company recently announced a definitive agreement to acquire Specialty Medijuana Products, Inc., which has submitted its evidence package as part of the Affirmation of Readiness to Health Canada. Upon successful review of this final stage, the company may expect to receive an ACMPR license to cultivate cannabis, which could be a significant value inflection point for the company.
This makes for a total of three ACMPR applicants to Choom’s already dynamic strategy.
The company continues to develop its two other facilities for cultivation, which will also provide the company with the potential to expand to meet market needs.
The first facility, located in Vernon, B.C., has 6,800 square feet of space. When working at full capacity, this facility is anticipated to produce revenue reaching $6.6 million, excluding income from oils. A second phase of building, slated for completion by the end of 2018, could increase this potential to $15 million.
A facility at Chemainus on Vancouver Island provides a second source of cannabis. With 4,500 square feet of space, this location is expected to provide revenue up to $4.5 million, not counting oils. Like the Vernon facility, it is undergoing a refit and should be ready for production for legalization in 2018; a second phase of building is planned for completion by early next year. This expansion could increase this facility’s potential revenue to $9 million.
Product and Placement
One of the pillars of Choom’s strategy is ensuring that it has the right product and position to sell to its specific market. To this end, the company has been working on its retail program to put Choom-branded stores onto Canadian streets.
The look of the stores is cool and stylish in keeping with Choom’s modern, young brand. Its custom-designed retail environment combines wood paneling with clean, white shelving and sofas where customers can relax to bring the Choom brand to life. Fitting with the aesthetic of popular modern brands, the stores will create a comfortable, familiar space for customers. The stores will also allow Choom to appeal to both existing cannabis users as well as those curious to try the product once it becomes legal.
With a complete and carefully branded supply chain that runs from cultivation to retail, Choom has laid the foundation for its goal to be a leader in the recreational-use cannabis industry.
Several other companies are also set to make the most of legalization through consumer brands and expansion strategies.
Hiku Brands (CSE: HIKU) (OTC: DJACF) is another cannabis lifestyle brand, with a focus on premium products in the form of its high-quality handcrafted cannabis flower. Hiku has a wholly owned subsidiary licensed to produce cannabis, which has requested a Pre-Sales License Inspection — the last step before licensing to sell cannabis under the ACMPR. Hiku recently closed on a $10 million strategic equity investment from Aphria (TSX: APH) (OTCQB: APHQF) to expand its product offering ahead of the recreational market.
As an established Canadian cultivator with a background in medical marijuana, Aphria continues to increase its production capabilities for the American cannabis market. The company recently received a license amendment under the ACMPR from Health Canada that will more than triple the company’s production capacity of medical cannabis from 9,000 kg annually to 30,000 kg annually.
Canopy Growth’s (TSX: WEED) (OTC: TWMJF) experience in developing and cultivating cannabis strains has set it up to produce for the newly expanding market. The company recently received a financial boost through a $191 million investment by Constellation Brands. This money from the company behind Corona, Modelo and Svedka will provide the money needed to develop cannabis-infused drinks, bringing the markets of the two companies together. This investment from a major player in the drinks industry shows the faith being placed in Canada’s recreational cannabis sector.
ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) is a cultivator of premium quality organic cannabis. Its ABcann Advantage technique is a best-in-class standardized approach to growing cannabis that uses computer monitoring and the omission of pesticides to minimize the risks of variance in its yields and ensure a consistently high-quality product. This has led to a 4.7 percent customer retention rate and 30 percent month-over-month customer growth.
The Canadian recreational cannabis industry is heading to the starting line with a strong pack of recreational brands and cultivators geared up to meet rising product demand. And as the sector grows, these companies could take a substantial share of a market worth billions.
For more information on Choom Holdings, please visit Choom Holdings (CSE: CHOO) (OTCQB: CHOOF)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
DORAL, FL, March 20, 2018 — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields as well as on R&D for certain medical devices, today announces the appointment of new Chief Operating Officer (COO) Gagan Hunter. This marks the achievement of a Q1 goal the company set at the commencement of 2018..
The Company’s current President, Director and COO Nickolas Tabraue relinquishes his role as COO to Mr. Hunter. Mr. Hunter will use his extensive experience and skill sets to maintain the Company’s operations with orderliness and efficiency while furthering the Company’s progress and expansion efforts. Mr. Tabraue will continue his role as president and director as he concentrates on implementing the Company’s growth strategy and further building the Company.
A graduate of Oaksterdam University, America’s first premier cannabis college, as well as a graduate of the University of Pittsburgh and having completed post-graduate studies at Temple University, Mr. Hunter is a holistic health specialist as well as a cannabis and cannabinoid educator. Mr. Hunter also has 20 years of natural products industry experience in sales, marketing and management along with 20 years of experience teaching nutrition. His skills, obtained through his 20 years in the industry, include staff training, purchasing, customer service, inventory control, and financial management.
Regarding his appointment, Hunter states, “I am truly excited to be part of the Earth Science Tech, Inc. team, and I have known and worked with Jill Buzan for more than 17 years and Gabriel Aviles for five years. Being part of the Company truly makes me feel at home and part of the family. I look forward to strengthening the Company’s operations and making sure efficiency stays consistent as growth continues.”
Tabraue adds, “I feel that we finally have the last piece of our puzzle in place to take ETST to new heights. Gagan has many great ideas to implement that will help the Company work more efficiently and with greater organization. We now have every major role managed by passionate, likeminded individuals to truly make ETST an innovative, trusted brand in the alternative medicine space. I plan on sharing updates regarding our audit, Tier II Reg A+, up-listing, and other working matters as they progress.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.
To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com
About Earth Science Pharmaceutical
Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.EarthSciencePharmaceutical.com
About Cannabis Therapeutics
Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.CannabisThera.com
About KannaBidioiD
KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
To learn more please visit: www.KannaBidioiDInc.com
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Dave Demarest
305.546.7640 Office
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, Chief Operating Officer
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Adds 27% more high-grade production to its strong North American silver and gold mines
COEUR D’ALENE, Idaho and VANCOUVER, British Columbia, March 19, 2018 — Hecla Mining Company (NYSE:HL) (Hecla) and Klondex Mines Ltd. (NYSE American:KLDX) (TSX:KDX) (Klondex) today announced Hecla will acquire all the outstanding shares of Klondex, a high-grade Nevada underground gold producer with its Fire Creek, Midas and Hollister mines, through a plan of arrangement (the Transaction). Klondex’s Canadian assets will be spun out to its existing shareholders.
Under the Transaction, Hecla will acquire Klondex for consideration of US$462 million with a mix of cash and shares of Hecla common stock and the newly formed company (Klondex Canada). Klondex’s shareholders will receive US$2.47 per share in cash or shares of Hecla, which represents a 59% premium to Klondex’s 30-day volume-weighted average price, as at March 16, 2018 on the NYSE American.
“Opportunities to acquire significant land packages along Nevada’s prolific gold trends are very rare. Rarer still are for these land packages to have the highest grade mines in the U.S. and this transaction is consistent with Hecla’s strategy of owning large prospective land packages with mines where we can improve costs, grow reserves and expand production,” said Phillips S. Baker, Jr., Hecla’s President and CEO. “We structured the deal to use our excess cash balance so our shareholders can benefit from the approximately 162,000 gold equivalent ounces a year of production while minimizing dilution.”
Mr. Baker continued, “One of our core strengths is operating high-grade, narrow-vein underground mines, and Klondex’s three operating mines – Fire Creek, Midas and Hollister – are some of the highest-grade gold mines in the world. After extensive due diligence, we see significant opportunity to improve costs, throughput and recoveries over time with our expertise. The combined approximately 110 square mile land position offers the opportunity to make discoveries and grow the reserve base as we improve our knowledge of the geology, something we have done at our other operations. We expect this transaction to be accretive on many important financial and credit metrics, with potentially significant synergies. We are pleased that two significant Klondex shareholders have committed to support this transaction, and look forward to welcoming other Klondex shareholders to our company.”
“This transaction is an excellent outcome for Klondex and our shareholders, delivering premium value and a clear pathway to develop and optimize the Nevada mining assets and create further value in the future,” said Paul Huet, Klondex’s President and CEO. “Hecla has a proven track record of developing and optimizing mining assets such as ours, and has a strong balance sheet that should help Fire Creek and our other properties reach their full potential. Hecla operates a diverse portfolio of some of the highest-grade mines in the world, and the addition of our assets strengthens the portfolio further. We are delighted to enter into this agreement and the Klondex board unanimously recommends that Klondex shareholders vote in favour of this transaction.”
A Further Transformation of Hecla
- Seven large land positions located in Alaska, Quebec, Nevada, Mexico and Idaho – Some of the safest and most prolific mining jurisdictions in the world.
- Proven operational excellence to be leveraged across expanded portfolio of high-grade mines – Hecla has an extensive track record of optimizing acquired assets as demonstrated at Casa Berardi and Greens Creek. Hecla’s expertise in narrow-vein mining and mill optimization will be applied to the acquisitions to improve the operational consistency and enhance the value of the expanded portfolio.
- Well capitalized pro-forma company with strong cash flow and solid balance sheet – Hecla expects to improve financial metrics with the Nevada mines’ cash flow.
- Significant production base with highly prospective growth opportunities and cost reductions – Adds about 162,000 oz of annual gold equivalent production. Hecla will launch a significant exploration program at Fire Creek and at the prospective Hatter Graben discovery at Hollister.
- Increased precious metals production – Peer group leading pro-forma production profile amongst intermediate precious metal producers of 762koz AuEq (2017A) or 54.1moz AgEq and commodity distribution of 30% Ag, 50% Au, 15% Zn and 5% Pb (by revenue).
Benefits to Hecla Shareholders
- Adds significant land position with extensive exploration and development potential, and production in Nevada, one of the most prolific gold mining jurisdictions in the world.
- Increases pro-forma 2017 annual production by 27%, equating to 162koz on a gold equivalent basis or 11.5 million ounces on a silver equivalent basis.
- Fire Creek is a cornerstone producing asset with robust cash flows and significant opportunities for exploration, mine life expansion, and increased throughput.
- The Transaction is structured to minimize dilution and is expected to be accretive on most important financial and operating metrics.
- Allows Hecla the opportunity to capture meaningful synergies.
- Further increases the grade of one of the highest-grade asset portfolios in the industry.
- Klondex’s assets leverage Hecla’s core competency in narrow-vein underground mining.
Benefits to Klondex Shareholders
- Immediate and significant premium of approximately 59% based on the 30-day volume weighted average price and approximately 72% based on closing prices on March 16, 2018, with ongoing participation in upside through Hecla shares and through Klondex Canada shares.
- Superior financial strength and flexibility to support critical development and exploration programs for Klondex’s assets.
- Hecla is well capitalized, with a lower cost of capital, making possible critical development and exploration programs for Klondex’s assets.
- Proven track record of successfully acquiring and optimizing underground assets.
- Superior investment with enhanced liquidity and a far more diversified production and financial base.
- Hecla has extensive experience operating efficient underground mines for over 125 years.
- Ownership in Klondex Canada, a gold company created to leverage Klondex’s exploration expertise and significant mining infrastructure assets in Canada.
Klondex Canada
Klondex is pleased to be forming Klondex Canada. Certain members of Klondex’s board and management team will continue on at Klondex Canada. Hecla will subscribe for US$7.0 million of common shares of New Klondex in exchange for a 13.46% equity interest, based on a pre-investment Klondex Canada valuation of US$45 million. Klondex Canada intends to make an application to list its shares on the TSX-V.
Terms of the Transaction
Klondex shareholders may elect to receive either US$2.47 in cash (Cash Alternative) or 0.6272 of a Hecla share (Share Alternative), each full Hecla share being currently valued at US$3.94, subject in each case to pro-ration based on a maximum cash consideration of US$157.4 million and a maximum number of Hecla shares issued of 77.4 million. If all Klondex shareholders elect either the Cash Alternative or the Share Alternative, each Klondex shareholder would be entitled to receive US$0.8411 in cash and 0.4136 Hecla shares. Klondex shareholders may also elect to receive US$0.8411 in cash and 0.4136 of a Hecla share and Klondex shareholders who fail to make an election will automatically receive US$0.8411 in cash and 0.4136 of a Hecla share. Klondex shareholders will also receive shares of a newly formed company (Klondex Canada) which will hold Klondex’s Canadian assets, including the True North and Bison Gold Resources properties.
At closing existing Hecla and Klondex shareholders will own approximately 83.8% and 16.2% of Hecla’s outstanding common stock, respectively.
Major Shareholder Support
CI Investments Inc. and Sentry Investments Inc., which together hold approximately 42.5 million shares of Klondex, representing approximately 23.7% of Klondex’s issued and outstanding shares, have entered into support agreements with Hecla, agreeing to vote their Klondex shares in favour of the Transaction. Each of Klondex’s directors and officers have also entered into an agreement to support the Transaction and the Board of Directors of Klondex has unanimously recommended that Klondex’s affected securityholders vote in favour of the transaction.
Board of Directors’ Recommendations
The Transaction has been unanimously approved by the Board of Directors of each of Klondex and Hecla. The Board of Directors of Klondex unanimously recommends that Klondex’s affected securityholders vote in favour of the Transaction.
GMP Securities L.P. and INFOR Financial Inc. have each acted as financial advisors to Klondex with GMP Securities L.P. and Maxit Capital LP having provided fairness opinions to the Board of Directors of Klondex and the Independent Committee of the Board of Directors of Klondex, respectively. CIBC World Markets Inc. and J.P. Morgan have each acted as advisors to the Board of Directors of Hecla and have provided fairness opinions to Hecla’s Board of Directors.
Each of the directors and senior officers of Klondex, who as of the date hereof, collectively hold approximately 1.7% of Klondex’s issued and outstanding common shares have entered into agreements to support the Transaction.
Transaction Conditions and Timing
The Transaction will be implemented by way of a Court-approved plan of arrangement under the Business Corporations Act (British Columbia) and will require the approval of: (i) 66 2/3% of the votes cast by the holders of Klondex’s common shares, (ii) 66 2/3% of the votes cast by the affected securityholders of Klondex voting as a single class, and (iii) if applicable, a majority of the votes cast by the holders of Klondex’s common shares after excluding any votes of Hecla and other persons required to be excluded under Canadian Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions, all at a special meeting to consider the Transaction.
The completion of the Transaction will also be subject to applicable regulatory approvals and closing conditions customary in transactions of this nature. The Arrangement Agreement provides for customary deal-protection provisions, including a non-solicitation covenant on the part of Klondex and a right for Hecla to match any superior proposal. The Arrangement Agreement includes a termination fee of US$21 million, payable by Klondex or Hecla, under certain circumstances.
It is anticipated that the special meeting of Klondex shareholders to consider the Transaction will be held in June 2018. The Transaction is expected to close in the second quarter of 2018.
No Financing Contingency
Hecla has sufficient cash on hand and available under existing credit arrangements to finance the cash portion of the consideration for the Transaction.
Section 3(a)(10) of the United States Securities Act of 1933, as amended (the Securities Act), exempts from the registration requirements of the Securities Act the issuance and exchange of securities which have been approved, after a hearing upon the fairness of the terms and conditions on which all persons to whom it is proposed the securities will be issued shall have the right to appear, by any Court expressly authorized by law to grant such approval. The parties expect this exemption to apply to Hecla’s issuance of shares in the Transaction and the issuance of shares of Klondex Canada as a result of the expected Court approval described below.
Advisors and Counsel
CIBC World Markets Inc. and J.P. Morgan are acting as financial advisors to Hecla in connection with the Transaction. Cassels Brock & Blackwell LLP is serving as Canadian counsel and K&L Gates LLP is acting as U.S. counsel to Hecla.
GMP Securities L.P. and INFOR Financial Inc. are acting as financial advisors to Klondex. Bennett Jones LLP is serving as Canadian counsel to the Independent Committee of the Board of Directors of Klondex and Dorsey & Whitney LLP is acting as U.S. counsel to Klondex.
Conference Call Details
Hecla and Klondex will host a conference call on Monday, March 19, 2018 at 8:30 a.m. Eastern Time to discuss the acquisition. You may join the conference call by dialing toll-free 1 855 760 8158 or 1 720 634 2922. The participant code is HECLA. Hecla’s live and archived webcast can be accessed at www.hecla-mining.com under Investors or via Thomson StreetEvents Network.
ABOUT HECLA
Founded in 1891, Hecla Mining Company (NYSE:HL) is a leading low-cost U.S. silver producer with operating mines in Alaska, Idaho and Mexico, and is a growing gold producer with an operating mine in Quebec, Canada. Hecla also has exploration and pre-development properties in seven world-class silver and gold mining districts in the U.S., Canada, and Mexico, and an exploration office and investments in early-stage silver exploration projects in Canada.
ABOUT KLONDEX
Klondex is a junior-tier gold and silver mining company focused on exploration, development, and production in a safe, environmentally responsible, and cost-effective manner. Klondex has 100% interests in three producing mineral properties: the Fire Creek Mine, the Midas Mine and ore milling facility, and the Hollister Mine, all of which are located in the state of Nevada, USA. Klondex also has a 100% interest in the True North Mine and mill in Manitoba, Canada and the Aurora Mine and ore milling facility, located in Nevada, USA.
Important Additional Information About the Transaction and Where to Find It
This material relates to Hecla’s proposed acquisition (the “Transaction”) of Klondex. Shares of Hecla’s common stock (the “Hecla Shares”) issued in connection with the proposed Transaction may be registered pursuant to a registration statement to be filed with the SEC or issued pursuant to an available exemption. This information is not a substitute for any registration statement or any other document that Hecla may file with the SEC or that it or Klondex may send to their respective shareholders in connection with the offer and/or issuance of Hecla Shares. Investors are urged to read any registration statement, if and when filed, and all other relevant documents that may be filed with the SEC or with Canadian regulatory authorities as and if they become available because they will contain important information about the issuance of Hecla Shares. Documents, if and when filed with the SEC, will be available free of charge at the SEC’s website (www.sec.gov) and under Hecla’s profile on the SEDAR website at www.sedar.com. You may also obtain these documents by contacting Hecla’s Investor Relations department at Hecla Mining Company; Investor Relations; 1-800-HECLA91 (1-800-432-5291); hmc-info@hecla-mining.com. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
In connection with the proposed transaction, Klondex will file proxy soliciting materials with the SEC and/or Canadian regulatory authorities. The information contained in any such filing may not be complete and may be updated, amended or changed. SHAREHOLDERS ARE URGED TO READ SUCH MATERIALS WHEN AVAILABLE AND ANY OTHER RELEVANT MATERIALS FILED WITH THE SEC AND/OR CANADIAN REGULATORY AUTHORITIES CAREFULLY IN THEIR ENTIRETY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.
Proxy solicitation materials will be mailed to Klondex’s shareholders seeking their approval of the proposed transaction. Anyone may also obtain a copy of such materials free of charge once available by directing a request to: Klondex Mines Ltd., 6110 Plumas Street, Reno, NV 89506, Attention: Investor Relations or, Hecla Mining Company, 6500 N. Mineral Drive, Suite 200, Coeur d’Alene, ID 83815-9408; Investor Relations; 1-800-HECLA91 (1-800-432-5291). In addition, any relevant materials filed with the SEC will be available free of charge at the SEC’s website at www.sec.gov and under Klondex’s profile on the SEDAR website at www.sedar.com. Interested persons may also access copies of such documentation filed with the SEC by visiting the Klondex’s website at www.klondexmines.com.
Participants in Solicitation
Hecla, Klondex, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Hecla is set forth in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 15, 2018, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 10, 2017, and its Current Report on Form 8-K, which was filed with the SEC on June 1, 2017. These documents may be obtained free of charge from the SEC’s website at www.sec.gov and Hecla’s website at www.hecla-mining.com. Information about the directors and executive officers of Klondex is set forth in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on March 15, 2018, its proxy statement for its 2017 annual and special meeting of shareholders, which was filed with the SEC on April 11, 2017 and its Current Report on Form 8-K, which was filed with the SEC on May 8, 2017. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Klondex proxy statement and other relevant materials to be filed with the SEC when they become available. These documents may be obtained free of charge from the SEC’s website at www.sec.gov and Klondex’s website at www.klondexmines.com.
Cautionary Statements Regarding Forward Looking Statements
Statements made or information provided in this news release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws. Words such as “may”, “will”, “should”, “expects”, “intends”, “projects”, “believes”, “estimates”, “targets”, “anticipates” and similar expressions are used to identify these forward-looking statements. Such forward-looking statements or forward-looking information include statements or information regarding the completion of the Transaction; additions to Hecla’s gold production and cash flow; the accretive nature of the Transaction; the realization of potential synergies, the impact of the Transaction on Hecla’s financial flexibility, cash flow, balance sheet and liquidity; and the exploration potential of Klondex’s land position. The material factors or assumptions used to develop such forward-looking statements or forward-looking information include that the Hecla’s plans for development and production will proceed as expected and will not require revision as a result of risks or uncertainties, whether known, unknown or unanticipated, to which the Hecla’s operations are subject.
Forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, expected or implied. These risks and uncertainties include, but are not limited to, metals price volatility, volatility of metals production and costs, litigation, regulatory and environmental risks, operating risks, project development risks, political risks, labor issues, ability to raise financing and exploration risks and results. Refer to Hecla’s Form 10K and 10-Q reports for a more detailed discussion of factors that may impact expected future results Neither Hecla nor Klondex undertakes any obligation to update forward-looking statements in this news release other than as may be required by law.
Similarly, please refer to the securities filings of Klondex for further information concerning risks applicable to it and its forward-looking information.
Information About Each Company
Information in this news release about Hecla has been provided by, and is the responsibility of, Hecla. For further information about Hecla, please refer to Hecla’s SEC filings, including its Annual Report on Form 10-K filed on February 15, 2018 and its filings with Canadian securities regulatory authorities under its issuer profile on SEDAR. Information in this news release about Klondex has been provided by, and is the responsibility of, Klondex. For further information about Klondex, please refer to Klondex’s SEC filings, including its Annual Report on Form 10-K filed on March 15, 2018 and its filings with Canadian securities regulatory authorities under its issuer profile on SEDAR.
Qualified Person (QP)
Pursuant to Canadian National Instrument 43-101, Dean McDonald, PhD, P.Geo., Senior Vice President – Exploration of Hecla Mining Company, who serves as a Qualified Person under National Instrument 43-101, supervised the preparation of the scientific and technical information in this news release as it relates to Hecla.
Pursuant to NI 43-101, Brian Morris, CPG, Senior Vice President – Exploration of Klondex, who serves as a Qualified Person under NI 43-101, supervised the preparation of the scientific and technical information in this news release as it relates to Klondex.
For further information, please contact:
Hecla:
Mike Westerlund
Vice President, Investor Relations
800-HECLA91 (800-432-5291)
Investor Relations
Email: hmc-info@hecla-mining.com
Website: www.hecla-mining.com
Klondex:
Mike Beckstead
Director, Investor Relations
O: 775-284-5757 | M: 406-290-4165
Email: mbeckstead@klondexmines.com
Website: www.klondexmines.com
– HTX-011 Achieved All Primary and Key Secondary Endpoints –
– HTX-011 Produced Statistically Significant Reductions in Both Pain Intensity and Need for Opioids through 72 hours Post-Surgery Compared to Placebo and Bupivacaine Solution, the Standard-of-Care –
– Significantly More Patients Receiving HTX-011 Were Opioid-Free through 72 hours after Surgery and Significantly Fewer HTX-011 Patients Experienced Severe Pain at Any Time –
– NDA Filing Targeted for 2H 2018 –
– Conference Call and Webcast Today at 8:30 a.m. ET –
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both Phase 3 trials, demonstrating statistically significant reductions in both pain intensity and the use of opioid rescue medications through 72 hours following surgery.
HTX-011 is the first and only long-acting local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control, through 72 hours.
The primary and key secondary endpoints for both Phase 3 studies were identical.
- The primary endpoint was pain intensity as measured by the Area Under the Curve (AUC) score from 0 to 72 hours post-surgery (AUC 0-72) compared to placebo.
Key secondary endpoints in order of evaluation were:
- comparison of AUC 0-72 of pain intensity to bupivacaine solution;
- the total amount of opioid rescue medication consumption compared to placebo through 72 hours after surgery;
- the proportion of patients who received no opioid rescue medication after surgery compared to bupivacaine solution; and
- the total opioid consumption through 72 hours after surgery compared to bupivacaine.
Bunionectomy (Study 301/EPOCH1) Results
EPOCH1 was a randomized, placebo- and active-controlled, double-blind, Phase 3 clinical study evaluating the efficacy and safety of locally administered HTX-011 at 60 mg compared to the standard dose of bupivacaine solution (50 mg) and placebo for post-operative pain control following bunionectomy surgery in 412 subjects. All primary and key secondary endpoints were achieved:
- There was a 27% reduction in pain intensity as measured by AUC 0-72 when comparing HTX-011 to placebo (p<0.0001).
- There was an 18% reduction in pain as measured by AUC 0-72 when comparing HTX-011 to bupivacaine solution (p=0.0002).
- Over 72 hours post-surgery, patients receiving HTX-011 consumed 37% less opioids than placebo patients (p<0.0001) and 25% less opioids than patients receiving bupivacaine solution (p=0.0022).
- 29% of patients receiving HTX-011 required no opioid medication for 72 hours post-surgery compared to only 2% receiving placebo (p<0.0001) and 11% receiving the standard-of-care, bupivacaine solution (p=0.0001). These results parallel the significantly reduced incidence of severe pain in patients receiving HTX-011 compared to both placebo (36% reduction; p<0.0001) and bupivacaine (29% reduction; p<0.0001).
Hernia Repair (Study 302/EPOCH2) Results
EPOCH2 was a randomized, placebo- and active-controlled, double-blind, Phase 3 clinical study evaluating the efficacy and safety of locally administered HTX-011 at 300 mg compared to the standard dose of bupivacaine solution (75 mg) and placebo for post-operative pain control following hernia repair surgery in 418 subjects. All primary and key secondary endpoints were achieved:
- There was a 23% reduction in pain intensity as measured by AUC 0-72 when comparing HTX-011 to placebo (p=0.0004).
- There was a 21% reduction in pain as measured by AUC 0-72 when comparing HTX-011 to bupivacaine solution (p<0.0001).
- Over 72 hours post-surgery, patients receiving HTX-011 consumed 38% less opioids than placebo patients (p=0.0001) and 25% less opioids than patients receiving bupivacaine solution (p=0.0240).
- 51% of patients receiving HTX-011 required no opioid medication for 72 hours post-surgery compared to only 22% receiving placebo (p<0.0001) and 40% receiving the standard-of-care, bupivacaine solution (p=0.0486). These results parallel the significantly reduced incidence of severe pain in patients receiving HTX-011 compared to both placebo (40% reduction; p<0.0001) and bupivacaine (19% reduction; p=0.0372).
HTX-011 was well tolerated in both studies, with a safety profile comparable to placebo and bupivacaine solution. There were no drug-related serious adverse events or discontinuations due to drug-related adverse events in HTX-011-treated patients, and there were fewer opioid-related adverse events in HTX-011-treated patients.
HTX-011 is the first and only long-acting anesthetic designed to address both postoperative pain and inflammation in a single administration at the surgical site. The unique synergy of bupivacaine and meloxicam in HTX-011 has consistently been shown to reduce pain over 72 hours significantly better than bupivacaine alone in multiple diverse surgical models. HTX-011 is administered as a single-dose application via needle-free syringe to directly coat the affected tissue within the surgical site prior to suturing, which makes HTX-011’s route of administration faster, easier and potentially safer compared to numerous injections required with current local anesthetics.
“Acute use of opioid pain medications for postoperative pain control is directly linked to over 2 million new persistent opioid users every year and up to 440,000 new cases of Opioid Use Disorder annually, making postoperative opioid use an important contributor to the opioid epidemic in the United States. In addition, with more than a billion opioid pills taken home after surgery every year for postoperative pain control, there is an enormous concern about diversion of these pills and a desperate need for effective non-opioid alternatives,” said Eugene R. Viscusi, MD, Professor of Anesthesiology and Chief of Pain Medicine in the Department of Anesthesiology at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA. “The Phase 3 results with HTX-011 suggest it may be a promising foundation in non-opioid multimodal pain management in a wide range of surgical procedures.”
“My family has endured unspeakable tragedy, losing our son, Tyler, to a heroin overdose that could have been prevented if he was not first exposed to opioids following a routine elbow surgery. Physicians, patients and families need new, more effective pain management options to address postsurgical pain so that we can lessen the number of people that are exposed to harmful opioids, stopping addiction before it starts,” said Travis Bornstein, Founder Hope United.
“With today’s results, HTX-011 is the only locally administered anesthetic to demonstrate superior pain relief and a reduction in opioid use as compared to not only placebo, but also the current standard-of-care, bupivacaine solution, in Phase 3 studies,” said Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics. “We look forward to submitting a New Drug Application for HTX-011 to the U.S. Food and Drug Administration in the second half of 2018. If approved, we believe that HTX-011 could have a significant impact on the opioid crisis by reducing the use of opioids after surgery, while at the same time allowing patients to experience less pain.”
Conference Call and Webcast
Heron Therapeutics will host a conference call and webcast today, March 19, 2018, at 8:30 a.m. ET (5:30 a.m. PT). The conference call can be accessed by dialing 877-311-5906 for domestic callers and 281-241-6150 for international callers. Please provide the operator with the passcode 1369799 to join the conference call. A slide presentation accompanying today’s press release and conference call may also be found on Heron’s website at www.herontx.com under the Investor Relations section. The conference call will also be available via webcast under the Investor Relations section of Heron’s website. An archive of today’s teleconference and webcast will be available on Heron’s website for 60 days following the call.
About HTX-011 for Postoperative Pain
HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of postoperative pain. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, HTX-011 was designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. HTX-011 has been shown to reduce pain significantly better than placebo or bupivacaine alone in three diverse surgical models: bunionectomy, hernia repair and abdominoplasty. HTX-011 is being investigated in ongoing Phase 2 studies in nerve block (breast augmentation) and total knee arthroplasty. The Phase 3 program for HTX-011 is now complete and Heron today reported positive topline data from its pivotal bunionectomy and hernia repair studies. HTX-011 was granted Fast Track Designation from the FDA in the fourth quarter of 2017. In the second half of 2018, Heron expects to file an NDA to the FDA for HTX-011.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. For more information, visit www.herontx.com.
Forward-Looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the timing of the HTX-011 NDA filing and review process, and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
David Szekeres
Senior VP, General Counsel, Business Development and Corporate Secretary
Heron Therapeutics, Inc.
dszekeres@herontx.com
858-251-4447
SAN GABRIEL, California, March 19, 2018 —
ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces that it is exploring investments into Cryptocurrency Mining with its recent purchase of ASIC (Application Specific Integrated Circuit) machines used to mine SHA-256 or Scrypt mining algorithms to earn cryptocurrencies such as Bitcoin and Litecoin.
The Company’s initial trial included the purchase of 20 BitMain L3+ Antminers and 7 BitMain S9 AntMiners that were installed inside a top of the line and secured datacenter near Seattle. Based on initial reports, the Company anticipates that this will be a successful venture that will open the door for the Company to consider adding 500 or more ASIC units and to make an additional investment in graphical processing units (“GPUs”) and other equipment suitable for blockchain mining that can achieve minimum hash rates consistent with the equipment specifications by the end of its fiscal year, May 31, 2018.
According to ChineseInvestors.com, Inc.’s CEO Warren Wang, “this initial step into cryptocurrency mining positions the Company to capitalize on a growing industry which could have tremendous upside potential. Moreover, the knowledge that CIIX is gaining and the professional contacts it is developing in the cryptocurrency space is synergistic with the educational content the Company provides subscribers on its crypto news platform, NewCoins168.com.
“The Company endeavors to be on the cutting edge of blockchain technology and to stay ahead of the curve in an effort to continue to build shareholder value and increase revenues this year.”
About ChineseInvestors.com (OTCQB: CIIX)
Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.
For more information visit ChineseInvestors.com
Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom
Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh
Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;
https://www.facebook.com/Chineseinvestors.com.english
Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776
Investor Relations:
Alan Klitenic
+1-214-636-2548
Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com
